Salivary gland regeneration
A hydrogel-encapsulated muscarinic agonist composition targets salivary gland progenitor cells to regenerate secretory units, addressing the inadequacies of current treatments for xerostomia by providing sustained saliva production and avoiding side effects, suitable for xerostomia caused by radiation or autoimmune diseases.
Patent Information
- Application Number
- CN201980091617.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-10
- Filing Date
- 2019-12-10
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-12-10
AI Technical Summary
Current treatments for salivary gland dysfunction, such as xerostomia, are inadequate as they lack regenerative therapies and cause adverse side effects, while existing muscarinic agonists provide only temporary relief and are not suitable for long-term use.
A composition comprising a muscarinic agonist encapsulated in a hydrogel, formulated for topical administration to the salivary glands, which targets acinar progenitor cells to regenerate secretory units and restore saliva production, using selective M1 and/or M3 muscarinic receptor agonists like Cevimeline or pilocarpine, optionally with alginate cross-linked by divalent cations, and potentially combined with a contrast agent for imaging.
The hydrogel delivery system provides sustained release of muscarinic agonists for up to 30 days, effectively regenerating salivary glands and restoring saliva production without significant side effects, suitable for treating xerostomia caused by radiation or autoimmune diseases like Sjögren's syndrome.
Smart Images

Figure CN113677371B_ABST
Abstract
Description
[0001] Cross-references to related patent applications
[0002] This patent application claims priority under 35 U.S.C. § 119(e) to Provisional Patent Application No. 62 / 777,459, filed on December 10, 2018; the contents of which are incorporated herein by reference in their entirety.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0004] This invention was made with government support, including grant U24DE026914 from the National Institutes of Health. The government has certain rights in this invention. Background Art
[0005] Salivary gland (SG) dysfunction severely impairs patients’ oral health and quality of life: saliva protects the oral mucosa, facilitates food digestion, aids in pronunciation, and contributes to the remineralization of dental hard tissues. Dry mouth or xerostomia may occur as a result of irreversible pathological damage caused by the autoimmune disease Sjögren’s syndrome (1-2 million cases in the United States) or therapeutic radiotherapy for head and neck cancer (in which the SG is inadvertently irradiated along with the tumor, 60,000 cases per year in the United States). Loss of the salivary glands’ regenerative capacity results in cessation of saliva production and significantly affects the quality of life of these patients. There are currently no available regenerative therapies for salivary dysfunction, so new, implementable solutions are needed.
[0006] Currently, the standard of care recommends palliative treatments such as saliva substitutes or artificial saliva and / or systemic sialagogues. Cevimeline and pilocarpine are two FDA-approved muscarinic agonists that promote temporary salivation. Pilocarpine is a nonselective muscarinic agonist, whereas cevimeline has a higher affinity for the M1 and M3 muscarinic receptor subtypes, both of which are expressed in the submandibular and sublingual salivary glands. Although these agents are effective in promoting short-term salivation when taken 3–4 times daily, they can cause adverse parasympathomimetic side effects, including hyperhidrosis, diarrhea, headache, and blurred vision, leading to reduced patient compliance. Recently, it has been reported that patients taking cevimeline or pilocarpine orally for a long period of time have improved salivary gland function (Barbe (2017) J Evidence Based Dental Practice. 17(3):268–270). Furthermore, continuous oral administration of pilocarpine to mice treated with head and neck gamma irradiation increased salivary flow compared with untreated controls (Taniguchi et al., 2019) Acta Histochimica et Cytochimica Sinica 52(3):45-58), suggesting that muscarinic agonism may promote salivary gland repair, although the mechanism by which this is achieved has yet to be determined.
[0007] Therefore, there remains a need for better treatments for salivary dysfunction, particularly regenerative treatments that can restore salivary acinar cells and saliva production. Summary of the invention
[0008] The present invention provides compositions and methods for regenerating salivary glands by promoting replacement of acinar cells. + Progenitor cells) are essential for the replenishment of acinar cells and have an unexpected ability to repopulate the tissue after radiation-induced injury. The results also found that cholinergic nerves play a critical role in controlling acinar cell replacement during homeostasis and that this neuronal influence can be replicated by adding cholinergic mimetics to acinar progenitor cells. Therefore, directly targeting acinar progenitor cells within the tissue with cholinergic agonists and / or muscarinic agonists may regenerate the secretory units of the salivary glands, allowing the restoration of functional salivary acini and the treatment of oral diseases such as xerostomia after radiation therapy or xerostomia associated with Sjögren's syndrome.
[0009] In one aspect, a composition comprising a muscarinic agonist encapsulated in a hydrogel is provided, which is formulated for topical administration to the salivary glands for treating xerostomia. Such a composition can be used to treat xerostomia, such as xerostomia caused by damage to the salivary glands caused by radiation or autoimmune diseases (e.g., Sjögren's syndrome).
[0010] In certain embodiments, the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes. In one embodiment, the muscarinic agonist is Cevimeline.
[0011] In certain embodiments, the muscarinic agonist is pilocarpine.
[0012] In certain embodiments, the hydrogel comprises alginate. The alginate can be ionically cross-linked with divalent cations. In certain embodiments, the alginate is cross-linked with divalent calcium cations (Ca 2+ ) for ionic cross-linking.
[0013] In certain embodiments, the concentration of alginate in the hydrogel ranges from about 2 wt % to about 10 wt % (weight percent), including any wt % within this range, such as 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 wt %.
[0014] In certain embodiments, the alginate is at least partially oxidized. In some embodiments, about 2% to about 10% of the alginate is oxidized, including any percentage within this range, such as 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5% or 10%. In one embodiment, about 2% of the alginate in the hydrogel is oxidized, and the concentration of the alginate is 5wt%.
[0015] In certain embodiments, the hydrogel delivers the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks or more after administration to the subject. In some embodiments, the hydrogel delivers the muscarinic agonist for up to 30 days.
[0016] In certain embodiments, the composition further comprises a contrast agent, for example, to confirm the localization of the composition relative to the salivary gland by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., suitable for ultrasound imaging) or a radiopaque contrast agent (e.g., suitable for radiography).
[0017] In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient.
[0018] On the other hand, a kit comprising a composition as described herein (which comprises a muscarinic agonist encapsulated in a hydrogel) and instructions for treating dry mouth is provided. In some embodiments, the kit further comprises a device for delivering the composition to the subject. For example, the kit may comprise a first syringe containing a composition (which comprises a muscarinic agonist encapsulated in an alginate hydrogel), a second syringe containing a solution (which comprises calcium chloride), and a Luer lock, wherein the second syringe may be connected to the first syringe by the Luer lock. The first syringe containing the composition (which comprises the muscarinic agonist encapsulated in an alginate hydrogel) may be stored frozen. In some embodiments, the muscarinic agonist in the kit is Cevimeline or Pilocarpine.
[0019] In another aspect, a method of treating dry mouth in a subject is provided, the method comprising topically administering to a salivary gland of the subject a therapeutically effective amount of a composition comprising a muscarinic agonist encapsulated in a hydrogel.
[0020] In certain embodiments, the composition is injected into or adjacent to the salivary gland.
[0021] In certain embodiments, multiple therapeutically effective doses of the composition are administered to the subject.
[0022] In certain embodiments, the xerostomia is caused by damage to the salivary glands due to radiation or Sjögren's syndrome.
[0023] In certain embodiments, the method further comprises performing medical imaging (eg, ultrasound imaging) or palpation to locate the salivary gland prior to injection.
[0024] In certain embodiments, a method for promoting salivary gland regeneration in a subject in need thereof is provided, the method comprising: locally administering at least one of a cholinergic agonist or a muscarinic agonist to acinar progenitor cells and acinar cells of the salivary gland to promote proliferation of the acinar progenitor cells and the acinar cells, thereby increasing saliva secretion.
[0025] In certain embodiments, the cholinergic agonist comprises at least one of acetylcholine or an acetylcholine analog. In some embodiments, the acetylcholine analog comprises carbachol.
[0026] In certain embodiments, the acinar progenitor cells are SOX2 + In some embodiments, the SOX2 + AQP5 + / Ki67 + In other embodiments, the cell comprises SOX2 + / AQP5 + / Ki67 + SOX2 in acinar progenitor cells + Acinar progenitor cells are mucin (MUC) 19 - cell.
[0027] In some embodiments, the method further comprises isolating SOX2 from the salivary gland of the subject being treated. + Acinar progenitor cells and expansion of the SOX2 + acinar progenitor cells, and then implanting the expanded cells into the salivary glands of the subject.
[0028] In some embodiments, prior to implantation, the expanded cells are provided in an engineered tissue construct or a biocompatible matrix that can control the release of at least one cholinergic agonist or muscarinic agonist in the expanded cells. The controlled release can include at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release. The engineered tissue construct or biocompatible matrix can include a biodegradable natural polymer or macromer, such as a biocompatible hydrogel.
[0029] In some embodiments, the subject treated by the methods described herein suffers from an oral disease, such as a disease that affects saliva production. Examples of oral diseases include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjögren's syndrome, sialadenitis, mumps, sialoductitis, sialadenitis, salivary gland stones, sialolithiasis, mucocele, sublingual cyst, hyposecretion, sialorrhea, drooling, xerostomia, benign lymphoepithelial lesions of salivary glands, salivary gland dilatation, salivary gland enlargement, salivary duct stenosis, and salivary duct stenosis. In other embodiments, the subject may have previously received radiation therapy that can cause xerostomia. The methods described herein can be used to treat such oral diseases (i.e., xerostomia) that affect saliva production suffered by human subjects. The methods described herein will also be used in veterinary applications to treat xerostomia suffered by domestic animals, including but not limited to pets (e.g., dogs and cats) and livestock (e.g., sheep, goats, pigs, horses, and cattle).
[0030] Other embodiments described herein relate to methods for promoting salivary gland regeneration in a subject in need thereof, the method comprising isolating and expanding SOX2+ acinar progenitor cells in the subject's salivary glands, and then implanting the expanded cells into the subject's salivary glands. + Acinar progenitor cells can be AQP5 + / Ki67 + / MUC19 - cell.
[0031] In some embodiments, at least one of a cholinergic agonist or a muscarinic agonist may be administered to the expanded cells before and / or after implantation of the expanded cells to promote acinar cell generation.
[0032] In other embodiments, the expanded cells may be provided in an engineered tissue construct or a biocompatible matrix. The engineered tissue construct or biocompatible matrix may controllably release the at least one cholinergic agonist or muscarinic agonist in the expanded cells, wherein the controlled release comprises at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figures 1A-1F showed that SOX2 marks progenitor cells that give rise to acinar but not ductal cells in the salivary glands of adults or adult animals. Figure 1A Representative images of adult submandibular (SMG), sublingual (SLG), and parotid (PG) salivary glands (non-IR, 28-33 years old) immunostained for SOX2, epithelial cells (E-cadherin; ECAD), or CD44 and nuclei. Single arrows indicate acinar cells expressing SOX2. Scale bar, 20 μm. Figure 1BWild-type mouse SMG and SLG stained for SOX2, ECAD, and nuclei. Arrows indicate cells expressing SOX2. Scale bar, 50 μm. The yellow dashed line indicates the boundary between SMG and SLG. Figure 1C Sox2 eGFP Sublingual salivary gland (SLG) immunostained for GFP and the differentiation acinar marker mucin 19 (MUC19). The white dashed line outlines the Sox2 eGFP+ Outlines of MUC19(-) cells. Scale bar = 20 μm. Figure 1D AQP5 + SOX2 + Total AQP5 + The percentage of acinar cells. Figure 1E Images of SLGs immunostained for SOX2, Ki67, and the epithelial cell marker E-cadherin (ECAD). White arrows indicate proliferating Ki67 + SOX2 + Cells. White lines outline individual cells and nuclei. Scale bar = 10 μm. Figure 1F Representative images of Sox2 lineage-traced SLGs. Immunostaining for SOX2, acinar markers AQP5 and MUC19, and ductal marker KRT8 was performed before Sox2 CreERT2 ;Rosa26 mTmG Recombination was induced in mice and salivary glands and followed for 24 hours and 30 days, respectively. * indicates MUC19(-)Sox2 CreERT2 GFP(+) cells. Scale bar = 30 μm. mT = membrane-bound Tomato. Data information: ( Figure 1D ) were counted using three non-consecutive sections from the SLG of adult female animals (n=5). Data are presented as mean±SD.
[0034] Figures 2A-2D It was shown that SOX2 and SOX2 + The cells are essential for the replenishment of salivary gland acinar cells. Figure 2A , 2B Sox2 CreERT2 ;Sox2 fl / fl ;Rosa26 mTmG / + Mouse ( Figure 2A ; see schematic) or Sox2 CreERT2 Rosa26 DTA ;Rosa26 mTmG / + Mouse ( Figure 2B ; see schematic diagram) Sox2 or SOX2 in SLG +Cell ablation. Sections were immunostained for AQP5, KRT8 or ECAD and nuclei. Scale bar = 50 μm. White dashed lines outline the ducts. n = 3 (per genotype). Figure 2C , 2D Sox2 CreERT2 ;Sox2 fl / fl ( Figure 2C ) or Sox2 CreERT2 Rosa26 DTA ;Rosa26 mTmG / + SLG( Figure 2D Quantification of ductal area in ( ) (expressed as a percentage of total epithelial area). Figure 2C ) in the middle, right, Sox2 CreERT2 ;Sox2 fl / fl SOX2 in SLG + The number of cells (expressed as a percentage of the total number of cells). Figure 2D ) In the right figure, wild type and Sox2 CreERT2 Rosa26 DTA ;Rosa26 mTmG / + KRT8 in mice + Catheter, AQP5 + and SOX2 + The total number of acinar cells was counted. Data information: The number of cells / duct area was calculated in three non-continuous fluorescent sections of each SLG from n = 3 mice / genotype. Figure 2C and 2D The data in ( ) (n=3) are mean ± SD and have been analyzed by Student t test. Figure 2C ), *P=0.011, **P=0.0041, and in ( Figure 2D ), left panel, **P=0.0015; right panel, ***P=0.0007, **P=0.0018.
[0035] Figures 3A-3H This suggests that parasympathetic nerves are required to maintain SOX2 + cells and is required for promoting SOX2-mediated acinar cell replacement. Figure 3A Schematic diagram showing the time course and location of the chorda tympani (CT) denervation in the adult mouse. Figure 3B Gene expression (qPCR) analysis of intact (undamaged contralateral gland) and nerve-transected SLG at 7 and 30 days post-surgery (D7 or D30). For each time point, gene expression was normalized to Rsp18 and intact controls. Figures 3C-3FImmunostaining of nerves (GFRa2), acinar cells (AQP5 and MIST1), ductal cells (KRT8), and epithelial cells (ECAD) was performed in control and transected SLGs 7 days after denervation. + 、AQP5 + 、MIST1 + 、KRT8 + and KRT5 + The number of cells was counted and expressed as a percentage of the number of cells in the control SLG ( Figure 3F ). Figure 3C , 3D Scale bars in 3E) = 25 μm. Figure 3G , 3H Before TUBB3 immunostaining, Sox2 CreERT2 ;Rosa 26mTmG Recombination was induced in mice (3 days after nerve transection) and SLG and followed for 11 days. GFP in control and transected glands + and mT + The percentage of acinar cells is shown in ( Figure 3G ). Figure 3H ) Scale bar = 25 μm. Data information: ( Figure 3B ) The data (n=5) are mean ± SEM and have been analyzed by one-way ANOVA and post hoc Dunnett's test. Sox2 (D7) * P = 0.0455, Tubb3 (D7) ** P = 0.0082, Tubb3 (D30) ** P = 0.0091, Vip (D7) ** P = 0.0098, Vip (D30) ** P = 0.0063, Vacht (D7) ** P = 0.0071, Muc19 (D7) * P = 0.0419, Aqp5 (D7) * P = 0.0468. ( Figure 3F and 3G The data in ) are calculated from the correlation results of three non-consecutive fluorescent sections per SLG from n=5 mice / group or genotype, are mean±SD, and have been analyzed by Student's t test. SOX2 + *P = 0.0197, AQP5 + *P=0.0106, %GFP + ***P=0.0000096, %mT + ***P = 0.0000096.
[0036] Figures 4A-4D Muscarinic signaling promotes SOX2 + Cell proliferation. Figure 4AAdult SLG was immunostained for SOX2, CHRM3, and nuclei. Images are 6 μm (left) and 1 μm (right) projections of 1 μm and 0.175 μm confocal sections. Scale bar = 10 μm. Figure 4B Flow cytometry was used to analyze epithelial SOX2 + Cells (CHRM1 + or CHRM3 + ) were counted and expressed as the percentage of total EpCAM + SOX2 + The percentage of cells. Figure 4C , 4D Immunostaining of SOX2, Ki67, and nuclei in adult SLGs from mice treated with pilocarpine or saline (control). White arrows indicate proliferating SOX2 + (SOX2 + Ki67 + )cell( Figure 4C ). Scale bar = 20 μm. ( Figure 4D ) After pilocarpine administration, SOX2 + and SOX2 + Ki67 + Cell fold change (unit: %). Data information: ( Figure 4B )SLG related data are pooled from n=3 mice (10,000 events). Figure 4D ) were calculated from three non-consecutive fluorescent sections per SLG from n=4 (saline) or n=5 (pilocarpine) mice, are mean±SD, and were analyzed by Student's t-test. *P=0.0487.
[0037] Figures 5A-5E These results suggest that Sox2 is essential for SLG regeneration after radiation injury. Figures 5A-5D Taken from wild type ( Figure 5A ) and Sox2 CreERT2 ;Rosa2 6mTmG ( Figure 5D ) Representative images of control (0 Gy; non-IR) and irradiated (10 Gy; IR) SLG of mice analyzed after 1, 3, and 14 days. ( Figures 5A-5C ) SLG was stained for nerve (TUBB3), SOX2, CyclinD1 (CCND1) and nucleus ( Figure 5A , 5C ), and calculate the neural density ( Figure 5B ). Figure 5C ) Quantification of SOX2 + and CCND1 +Cell number. Figure 5D ) after irradiation (IR), Sox2 CreERT2 ;Rosa26 mTmG Mice were cultured for 14 days and immunostained for SOX2 ( Figure 5D , red). White arrows indicate SOX2-negative offspring. ( Figure 5A and 5D ) The scale bar is 50 μm. Figure 5E Sox2 CreERT2 ;Sox2 fl / fl Mice and wild-type littermates were irradiated with 10 Gy IR, and SLG was analyzed 13 days later. SLG was immunostained for SOX2, AQP5, and nuclei. Scale bar = 50 μm. Data information: ( Figure 5B The data in ) are mean ± SD, where n = 3, and each value is plotted. ( Figure 5C The data in ) are calculated from the correlation results of three non-consecutive fluorescent sections per SLG from n=3 mice / treatment regimen, and are mean ± SD, and have been analyzed by one-way ANOVA and post hoc Dunnett's test. SOX2 + (D1) *P=0.0487, SOX2 + CCND1 + (D3) *P=0.318, SOX2 + CCND1 + (D7)*P=0.0291.
[0038] Figures 6A-6C It shows that SOX2 + Progenitor cells can replenish acinar cells after radiation-induced injury in response to muscarinic stimulation. Fig. 6A After a single 15 Gy IR, the cells from Sox2 CreERT2 ;Rosa26 mTmG Mouse SLG, explant culture 0-48 hours. Schematic diagram showing the timeline of recombination, culture, and analysis. Figure 6B Representative images of lineage-traced explants immunostained for nuclear staining. Scale bar 50 μm. Figure 6C GFP + Quantification of cell number. Data information: ( Figure 6C ) were calculated from three random areas of n = 3 immunostained explants in each treatment scheme, and each value is plotted and analyzed by one-way ANOVA and post hoc Dunnett's test. Error bars represent mean ± SD. Non-IR vs. IR***P = 0.0022, IR vs. IR+CCh**P = 0.0058, IR vs. IR+4-DAMP***P = 0.0010.
[0039] Figures 7A-7E Show that acetylcholine / muscarinic signaling maintains SOX2 and the acinar lineage in human SGs. Fig. 7A qPCR was performed on human salivary glands obtained from healthy individuals (non-IR; submandibular) or patients receiving radiation therapy for head and neck cancer (IR). Figures 7B-7D Human SMG explants were cultured with embryonic day (E) 13 mouse parasympathetic ganglia (neural) or E13 mesenchymal stem (MES) for 7 days. Figure 7B , TUBB3) or cell proliferation ( Figure 7C , Ki67) markers by immunostaining or by qPCR ( Fig.7D ) Explants were analyzed. Scale bar = 50 μm ( Figure 7B , 7C ). Fig. 7E qPCR analysis of adult salivary gland (SMG or PG) explants from four different individuals cultured for 4 hours (±CCh, 200 nM, n=4). For separate datasets, see Fig.14D . Data information: ( Fig. 7A ) n=11 (non-IR), n=7 (IR); 30-85 years old. Data were normalized to GAPDH and individual values are plotted and analyzed by Student's t-test with a false discovery rate set to 0.05. Error bars represent mean ± SD. AQP3 P=0.017, MIST1 P=0.086, AMY1 P=0.005, SOX2 P=0.079, CHRM1 P=0.040, CHRM3 P=0.011, EGFR P=0.931, KRT19 P=0.618. ( Fig.7D ) are mean ± SD of n = 2 individuals, where solid bars represent individual 1 and dashed bars represent individual 2. Data were normalized to salivary glands cultured with murine mesenchyme from the same individuals (control, black dashed line). Fig. 7E ) is a box plot of the relevant results of n=4 different individuals, which shows the mean (horizontal line), upper and lower quartiles (squares), and upper and lower limits (box whiskers). The data were normalized relative to the untreated control (black dashed line). n=5-8 explants / individual. Data analysis was performed by one-way analysis of variance and post hoc Dunnett's test. SOX2**P=0.00834, CHRM3*P=0.0449, CHRM1**P=0.0093, AQP5**P=0.0069, AQP3*P=0.0375, MIST1*P=0.0379, CD44*P=0.0485, KRT19*P=0.0461
[0040] Figures 8A-8B It shows that SOX2 + Short-term ablation of cells results in reduced acinar cell replacement. Fig. 8A )Sox2 CreERT2 ;Sox2 fl / fl ;Rosa26 mTmG / + SOX2 in mouse SLG + Cells were ablated over 3 days and SLGs were analyzed on day 4 (see schematic). CreERT2 ;Sox2fl / fl;Rosa26 mTmG / + SLG sections were immunostained for SOX2 and myoepithelial cells (α-smooth muscle actin; SMA). Scale bar = 50 μm ( Figure 8B )Sox2 CreERT2 Rosa26 DTA ;Rosa26 mTmG / + SOX2 in mouse SLG + Cells were ablated over 4 days and SLGs were analyzed on day 5 (see schematic). CreERT2 Rosa26 DTA SLG sections were immunostained for SOX2 and acinar cells (aquaporin 5; AQP5) or subjected to qPCR. Scale bar = 50 μm. Data information: Relative to Gapdh and wild-type controls, Figure 8B The data are normalized to those in Figure 2. Data are mean ± SD (n = 1, 3 technical replicates).
[0041] Figures 9A-9C showed that reinnervation 30 days after chorda tympani transection restored the acinar lineage ( Figures 9A-9C ) Immunostaining of SLG for SOX2, TUBB3, AQP5, MIST1 and ECAD ( Fig.9A ) and measured 30 days after denervation
[0042] SOX2 + 、AQP5 + 、MIST1 + and KRT8 + Cell number ( Fig. 9B ) and acinar cell size ( Fig. 9C ). n = 5 mice / time point / condition. Cell counts were performed in 3-4 fields of view per animal. Data information: Fig. 9B and Fig. 9C The data in n=5. Fig. 9B The data in are mean ± SEM and have been analyzed by one-way ANOVA test, Fig. 9CData in are box plots of related results from n=5 mice, showing mean±SEM, and have been analyzed by students t-test. *p=0.0498.
[0043] Figures 10A-10F showed that SOX2 marks a subset of acinar cells that replenish the acini. Fig. 10A Wild-type mouse PG stained for SOX2, ECAD, and nuclei. Scale bar, 50 μm. Fig. 10B Acinar SOX2 using FACS + and SOX2 - Cells (Ki67 + ) were counted and expressed as the percentage of total AQP5 + SOX2 + or AQP5 + SOX2 - The percentage of cells. Fig. 10C SOX2 + Acinar cells (CyclinD1 + CyclinD1 - ) is the percentage (%) of. Fig. 10D Rosa26 mTmG Schematic diagram of Cre-mediated gene deletion (adapted from Muzumdar et al., 2007). Fig.10E Representative images of SOX2 lineage-traced SLGs. CreERT2 ;Rosa26 mTmG Cre-mediated recombination was induced in mice and SLG and analyzed after 14 or 30 days. Scale bar = 25 μm. Fig.10F Representative images of the Kit lineage-traced SLG and SMG. CreERT2 ;Rosa26 mTmG Cre-mediated recombination was induced in mice and SMG / SLG and analyzed 14 days and 6 months later. Tissues were stained with AQP5 to mark acinar cells and KRT8 to mark intercalated ductal cells. Scale bar = 25 μm. mT = membrane-bound Tomato. Data information: ( Fig. 10B ), SLG related data were pooled from n=2 mice (85,000 events). ( Fig. 10C ) were calculated from correlation results of three non-consecutive fluorescent sections per SLG from n=3 mice, and individual values are plotted. Error bars represent mean±SD.
[0044] Figures 11A-11D showed that despite the presence of neural, Sox2 or SOX2 +Ablation of cells still resulted in reduced acinar cell replacement. Figures 11A-11C Sox2 CreERT2 ;Sox2 fl / fl ;Rosa26 mTmG / + Mouse ( Figure 2A ; see schematic) or Sox2 CreERT2 ;Rosa26 DTA ;Rosa26 mTmG / + Mouse ( Figure 2B ; see schematic diagram) Sox2 or SOX2 in SLG + Cell ablation. Fig.11A , 11B ) for WT, Sox2 CreERT2 ;Sox2 fl / fl and Sox2 CreERT2 ;Rosa26 DTA SLG sections were immunostained for SOX2 or TUBB3 and nuclei. White arrows indicate SOX2 + The white dashed square in the right image is magnified to highlight the remaining SOX2 in the tissue. + Fewer cells and non-nuclear (green) staining indicates the presence of debris. Scale bar = 50 μm. ( Fig. 11C ) The raw integrated density of neurons was calculated using ImageJ. Fig.11D Cyclin D1 (CCND1) and nuclear immunostaining for WT or Sox2 CreERT2 ;Sox2 fl / fl SLG. Dashed line = catheter; Arrow = CCND1 + Acinar cells. Scale bar = 50 μm. Data information: ( Fig. 11C ), WT n=4, Sox2 fl / fl n=4, DTA n=3. Individual values are plotted and expressed as mean±SD, and data analysis was performed by one-way ANOVA and post hoc Dunnett's test. **P=0.0091. ( Fig.11D Data in ) are representative images from n = 4 mice.
[0045] Figures 12A-12H showed that chorda tympani transection resulted in depletion of acinar cells within 7 days. Fig. 12A , 12C , 12D, 12G ) Seven days after denervation, control and nerve-transected SLGs were subjected to tyrosine hydroxylase (TH; Fig. 12A ), SOX2 and TUBB3( Fig. 12C )、KRT5( Fig.12D ), caspase-3 (CASP3; Figure 12G), epithelial cells (ECAD), and nuclear immunostaining. Acinar cell size was quantified in the SLG of adult wild-type (WT) mice with intact or transected chorda tympani (CT) 7 days after denervation ( Fig. 12B ). Fig. 12A , 12C , 12D, 12G) scale bar = 25 μm. ( Fig.12E , 12F ) Before TUBB3 immunostaining, Sox2 CreERT2 ;Rosa26 mTmG Recombination was induced in mice (24 hours before nerve transection) and SLG and followed for 15 days. + and mT + The percentage of acinar cells is shown in ( Fig.12F ). Fig.12E ) Scale bar = 25 μm. (H) Fold changes in expression of genes involved in cell cycle and apoptosis 7 days after denervation compared to intact controls. Dashed lines represent intact controls. Data information: ( Fig. 12B , 12F and 12H) in which the data n=5. Fig. 12B The data in ) are box plots of the results of n=5 mice, which show the mean value (horizontal line), upper and lower quartiles (squares), and upper and lower limits (boxes and lines), and have been analyzed by Student's t test. ***P=0.00000347. ( Fig.12F ) are mean ± SD and were analyzed by Student t test. % GFP + ***P=0.0000208, %mT + ***P=0.0000208. Fig.12H ) in the normalized form. Ccnd1*P=0.0477.
[0046] Figures 13A-13E showed that IR can induce cell damage and neuronal loss, and SOX2 and SOX2 + Progenitor cells can recruit mouse acinar cells in response to cholinergic mimetics. Fig.13A , 13B Transcriptional changes of murine SLG were analyzed by qPCR at days 0, 1, 3, and 7 after 10 Gy IR. Figures 13C-13E The cells were cultured for 48 hours and the smooth muscle actin (SMA, Fig. 13C )、SOX2( Fig.13D ) or Ki67( Fig.13E ) and nuclear immunostaining of Sox2 CreERT2 ;Rosa26mTmG Mouse SLG explants. Recombination was induced 24 hours before harvesting SLG for culture. Scale bar = 50 μm. Data information: ( Fig.13A and 13B ) in the data standardization. Fig.13A and 13B ) are mean ± SEM and were analyzed by one-way ANOVA and post hoc Dunnett's test. Bax(D1)**P=0.00826,Bax(D3)**P=0.0871,Pmaip1(D3)*P=0.0369,p21(D3) *P=0.0481, p53(D1)*P=0.0337, MKi67(D1)*P=0.0319, Sox2(D1)**P=0.0072, Sox2(D3)*P=0.0418, Aqp5(D1)*P=0.0421, Mist1(D1)*P=0.0432, Tubb3(D1) *P=0.0467, Tubb3(D3)*P=0.0470, Tubb3(D7)*P=0.0489, Vip(D1)*P=0.0402. ( Fig. 13C , 13D Images in 13A and 13E) are representative of three experiments, n = 3 SLG fragments / experiment.
[0047] Figures 14A-14D showed that muscarinic activation is sufficient to increase SOX2 expression and the acinar lineage in human adult salivary glands. Fig.14A qPCR was performed on human salivary glands obtained from healthy individuals (non-IR; submandibular) or patients receiving radiation therapy for head and neck cancer (IR). Fig. 14B Representative images of adult (h) salivary glands (non-IR, 22-31 years old; SMG) immunostained for endogenous SOX10, MIST1, EGFR, CD44, KRT7, AQP3, KRT5, ECAD, and nuclei. Single arrows indicate acinar and ductal cells expressing SOX10. Scale bar = 50 μm. Fig. 14C Ki67 in neural co-culture + Quantification of cell number ( Figure 7C Representative images shown in ). Fig.14D Adult salivary gland explants (SMG or PG) from four individual patients (healthy, non-IR) were cultured for 4 hours (±200 nM CCh). Summary data are available at Fig. 7E . Data information: ( Fig.14A) n=11 (non-IR), n=7 (IR); 30-85 years old. Data were normalized to GAPDH and individual values are plotted and analyzed by Student's t-test with a false discovery rate set to 0.05. Error bars represent mean ± SD. TUBB3 P=0.346, VIP P=0.461, GFRA P=0.002, TH P=0.433. ( Fig. 14C The data in ) are n=3 and mean±SEM, and have been analyzed by Student t-test. *P=0.0151. ( Fig.14D ) (n=4 individual individuals) were normalized to GAPDH expression and salivary glands from the same individuals cultured in triplicate in the absence of CCh (control; black dashed line) and are presented as mean±SD.
[0048] Figures 15A-15B Intraglandular injection of cevimeline promotes proliferation of acinar cells in mouse salivary glands. Mice were intraglandularly injected with cevimeline (CV) or saline (S, control). Mice were sacrificed 18 hours later, and proliferating cells were quantified in tissue sections (3 sections / gland, 3 mice / treatment). Scale bar = 60 μm ( Fig.15A Representative images shown in; Fig. 15B Comparison of the percentage (%) of acinar cells under the conditions of cevimeline administration and saline administration shown in FIG).
[0049] Figures 16A-16D The physical degradation of oxidized alginate (OA) hydrogels was demonstrated. Fig.16A ) Effect of oxidation on physical degradation, wt% kept constant at 5wt%. ( Fig. 16B )wt% effect on physical degradation, OA% was kept constant at 2% OA. ( Fig. 16C ) In vitro and in vivo degradation of 2% OA at 5wt%. Fig.16D ) Stability of 2% OA (5 wt %) under refrigerated (4°C) and frozen (-20°C) conditions.
[0050] Figures 17A-17D Cevimeline release from oxidized alginate (OA) hydrogels was demonstrated. Fig.17A ) Effect of oxidation on the release of cevimeline, wt% kept constant at 5wt%. ( Fig. 17B )wt% on the effect of Cevimeline, OA% was kept constant at 2% OA. ( Fig. 17C ) Effect of increasing initial cevimeline loading on the release kinetics of 2% OA hydrogel at 5wt%. Fig.17D) Cevimeline release from 2% OA hydrogels (5 wt %) with different initial Cevimeline concentrations each time.
[0051] Figures 18A-18C The results showed that the release of cevimeline from most alginate promoted glandular cell proliferation for 3 days. Alginate (ALG, 5% WT: 2% OA) or alginate + cevimeline (ALG + CV) was injected into the salivary glands adjacent to the Fig.18A ). The red circle highlights the injected alginate. Mice were sacrificed on day 3 and the proliferating Ki67+ and EdU+ cells were quantified ( Fig.18B and Fig.18C , 3 sections / gland, 3-4 mice / treatment regimen). Students t test comparing +CV vs. ALG control, *p<0.05. Scale bar = 40 μm.
[0052] Figures 19A-19E The results showed that alginate (with or without cevimeline) can induce a pro-reparative inflammatory response 7 days after injection. Alginate (ALG, 5% WT: 2% OA) or alginate + cevimeline (ALG + CV) were injected adjacent to the salivary glands. Mice were sacrificed on day 7. Salivary gland tissue sections were analyzed for CD3+ T cells ( Fig.19A and 19B ), CD68+ macrophages ( Fig.19C and 19D ) or CD206+ repair macrophages ( Fig.19E ) and nuclear immunostaining. Macrophage density was quantified and compared to saline injected animals of the same age (ip) or 22 month old mice (3 sections / gland, 3-4 mice / treatment). One-way ANOVA test comparing +CV vs ALG control vs control, *p<0.05, **p<0.01, ****p<0.00001. Scale bar = 40 μm.
[0053] Figures 20A-20F This suggests that cevimeline can promote acinar cell proliferation after radiation-induced damage. Fig. 20A ) Schematic diagram of radiation therapy. Fig. 20B ) Citrate-stimulated saliva secretion was reduced in 6-8 week old C57 / BL6 female mice 13 days after radiation treatment with a dose of 10 Gy. Figures 20C-20F ) After 14 days, the animals were intraperitoneally ( Fig. 20B and 20D ) or intraglandular ( Fig. 20C and 20D) were injected with saline or 10 mg / kg cevimeline. 18 hours after injection, animals were euthanized for tissue processing and immunofluorescence. Proliferation and SOX2+ cells were quantified in tissue sections (3 sections per animal).
[0054] Figures 21A-21D showed that treatment of irradiated salivary glands with alginate + cevimeline promoted acinar cell proliferation and improved salivary flow. Fig.21A A schematic diagram of the timeline of dosing of mice is shown. Mice were injected with alginate or alginate + cevimeline 14 days after radiation treatment and then sacrificed on day 3 for proliferation analysis. Fig.21B It was shown that alginate + cevimeline increased the corresponding proliferation rate compared to the proliferation rate level obtained by applying alginate alone. Fig. 21C The percentage of epithelial cells after treatment with alginate + cevimeline was compared with that after treatment with alginate alone. Fig.21D Data related to saliva measured 1 day before and 7 days after subcutaneous injection of saline, alginate or alginate + cevimeline 13 days after radiation treatment are presented. Two-way ANOVA, no RM, p = 0.0244 for the time parameter.
[0055] Fig. 22 Proliferation was not increased with the addition of cevimeline. Alginate containing 10 mg or 25 mg / kg was delivered to mice and proliferating (Ki67+) acinar cells were quantified on day 3.
[0056] Fig.23 It shows that alginate can promote the proliferation of acinar cells.
[0057] Fig.24 showed that alginate (with or without cevimeline) did not negatively affect the health of mice.
[0058] Fig.25 Demonstrated the analysis of alginate oxidation efficiency 13 C nuclear magnetic resonance (NMR) spectroscopy: 3-(Trimethylsilyl)propionic acid-d4 sodium salt (0.05 w / v%) was used as an internal standard.
[0059] Fig.26 A pair of syringes for producing injectable hydrogels is shown. A syringe containing a calcium crosslinking solution for producing the hydrogel is connected via a Luer lock to a second syringe containing alginate and a neurotransmitter mimetic (e.g., cholinergic agonist and / or muscarinic agonist) solution.
[0060] The location of canine and human salivary glands is shown in Figure 27. 1.5 ml to 2 ml of alginate hydrogel can be injected directly into the submandibular gland of a human or canine subject.
[0061] Fig.28 The results show that the salivary glands of dogs and humans are similar. The parotid and sublingual glands of dogs and humans appear to be most similar. The submandibular gland of dogs is similar to that of humans in that it is a mixed cell gland.
[0062] Fig.29 Demonstrated injection of alginate hydrogel into the canine submandibular gland.
[0063] Implementation
[0064] The present invention provides compositions, methods and kits for regenerating salivary glands by promoting replacement of acinar cells. The inventors have shown that progenitor cells in adult salivary glands (including SOX2 + Acinar progenitor cells are essential for the replenishment of acinar cells, with an unexpected ability to repopulate the tissue after radiation-induced injury (Example 1). The inventors have also shown that cholinergic nerves play a crucial role in controlling acinar cell replacement during homeostasis, and that this neuronal influence can be replicated by adding cholinergic mimetics to acinar progenitor cells. Therefore, it is possible to directly target progenitor cells within tissues (including SOX2) with cholinergic agonists and / or muscarinic agonists. + Acinar progenitor cells) can regenerate the secretory units of the salivary glands, thereby restoring functional salivary gland acini and treating oral diseases, such as xerostomia after radiation therapy or xerostomia associated with Sjögren's syndrome. In particular, a formulation comprising a muscarinic agonist (e.g., cevimeline) encapsulated in an alginate hydrogel can be formulated for topical administration to the salivary glands and for treating xerostomia (Example 2).
[0065] Before describing the compositions, methods and kits of the present invention, it should be understood that the present invention is not limited to the specific methods or compositions described, because there will be differences in actual implementation. It should also be understood that the terms used herein are only used to describe specific embodiments and are not intended to limit the inventive concept. The scope of the present invention will be limited only by the appended claims.
[0066] Where a numerical range is provided, it is to be understood that each intermediate value between the upper and lower limits of the range and the intermediate values within the range are included within the scope of the present invention. Unless the context clearly specifies otherwise, each intermediate value should be as low as one tenth of the lower limit unit. The present invention encompasses each smaller range between any of the values or intervening values within the range and any other values or intervening values within the range. The upper and lower limits of these smaller ranges may be independently included within the range or excluded within the range, and are also included within the present invention, subject to the requirements of any specifically excluded limits within the range. Where the range includes one or two limits, the range excluding any one or two of those included limits is also included within the present invention.
[0067] Unless otherwise defined, all technical and scientific terms used in this patent have the same meaning as those commonly understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described in this patent can also be used in the implementation or testing of the present invention, some potential and preferred methods and materials are described below. All publications mentioned in this patent are incorporated herein by reference to disclose and describe the methods and / or materials related to the cited publications. It should be understood that when there is a conflict, the present invention shall replace any disclosure in the cited publications.
[0068] After reading the present invention, the following will be apparent to those skilled in the art that each individual embodiment described and listed herein has layered components and features that can be quickly decomposed or combined with the features of any of the other several embodiments without departing from the scope and spirit of the present invention. Any stated method can be implemented in the order of events stated or in any other order that is logically possible.
[0069] It must be noted that the singular forms "a", "an", and "the" as used in this patent and the appended claims include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, and "the agonist" refers to one or more agonists and equivalents thereof known to those skilled in the art, such as ligands or activators, and the like.
[0070] The publications discussed in this patent are provided solely for their disclosure prior to the filing date of the patent. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0071] definition
[0072] The term "about," particularly when referring to a given quantity, is intended to encompass a deviation of plus or minus 5 percent.
[0073] The term "pharmaceutical agent" refers to all substances that can be used to prepare pharmaceutical and diagnostic compositions, or can be all substances that are compounds (such as small synthetic or naturally derived organic compounds), nucleic acids, polypeptides, antibodies, fragments, isoforms, variants or other substances that can be used independently for these purposes, all of which are within the scope of the present invention.
[0074] The term "agonist" refers to a substance that binds to a specific receptor and triggers a cellular response. It can mimic the effects of endogenous ligands (such as hormones or neurotransmitters) that bind to the same receptor. A "full agonist" binds to (has affinity for) a receptor and activates it, showing full efficacy on that receptor. An example of a drug that is a full agonist is isoproterenol, which mimics the effects of acetylcholine on beta adrenergic receptors. "Partial agonists" (such as buspirone, aripiprazole, buprenorphine, or norclozapine) also bind to and activate a given receptor, but only produce partial efficacy on the receptor relative to a full agonist.
[0075] A "partial agonist" can also be thought of as a ligand that exhibits both agonist and antagonist effects - when both a full agonist and a partial agonist are present, the partial agonist actually acts as a competitive antagonist, competing with the full agonist for receptor occupancy, resulting in a net reduction in receptor activation observed when the full agonist is used alone. A "co-agonist" works with other co-agonists to produce the desired effect. Antagonists prevent receptors from being activated by agonists. Receptors can be activated or inactivated by endogenous (such as hormones and neurotransmitters) or exogenous (such as drugs) agonists and antagonists, thereby stimulating or inhibiting biological responses. A ligand can act as both an agonist and antagonist for the same receptor, depending on the effector pathway.
[0076] The potency of an agonist is usually measured by its EC 50 For a given agonist, this can be calculated by determining the concentration of agonist required to elicit half of the maximal biological response of the agonist. EC 50 EC values can be used to compare the potency of drugs with similar efficacy to produce physiologically similar effects. 50 The smaller the value, the more potent the agonist is and the lower the drug concentration required to elicit a maximal biological response.
[0077] As used herein, "biocompatible matrix" refers to a material suitable for implantation in a subject on which a cell population can be deposited, which can be used to encapsulate one or more cholinergic agonists and / or muscarinic agonists. Once implanted in a subject, the biocompatible matrix does not cause toxicity or harmful effects. In one embodiment, the biocompatible matrix is a polymer whose surface can be molded into a desired structure that needs to be repaired or replaced. The polymer can also be molded into a part of the structure that needs to be repaired or replaced. In another embodiment, the biocompatible matrix undergoes linear deformation to fill the salivary glands and is distributed throughout the gland. The biocompatible matrix can release one or more cholinergic agonists and / or muscarinic agonists slowly, and can also provide a supportive framework that allows cells to attach and grow thereon. In some embodiments, the cultured cell population grows on a biocompatible matrix that provides the appropriate gap distance required for cell-cell interaction.
[0078] The term "differentiation" or "transdifferentiation" as used herein generally refers to the process by which a precursor or progenitor cell differentiates into a specific cell type. The term may refer to the process by which an acinar progenitor cell (e.g., an acinar progenitor cell expressing SOX2) becomes a differentiated acinar cell. Differentiated cells can be identified by their gene expression patterns and cell surface protein expression. The term "differentiation" as used herein refers to having characteristics or functions that are different from the original type of tissue or cell. Therefore, "differentiation" refers to the process or behavior of differentiation.
[0079] The term "modulate" refers to upregulation (i.e., activation or stimulation), downregulation (i.e., inhibition or prevention), or a combination or separation of both of a response, for example, the ability to be altered by upregulating or downregulating the activity of a protein, a nucleic acid encoding a protein, a pathway, a protein within a pathway, etc.
[0080] The phrase "oral tissue cells" refers to any cell population derived from the oral cavity. These include one or more different cell types that can be isolated from salivary glands, submandibular glands, sublingual glands, lingual glands, labial glands, buccal glands, palatine glands, striate ducts, excretory ducts, dental pulp tissue, dentin, periodontal tissue, bone, cementum, gingival submucosa, oral submucosa, tongue, and taste bud tissue. In a preferred embodiment, the oral tissue cells are derived from salivary glands. Examples of oral tissue cells include, but are not limited to, myoepithelial cells, epithelial cells, and the like.
[0081] The phrase "oral tissue" refers to any collection of cells that form a structure in the oral cavity. For example, oral tissue includes salivary glands, submandibular glands, sublingual glands, lingual glands, labial glands, buccal glands, palatine glands, striate ducts, excretory ducts, dental pulp tissue, dentin, periodontal tissue, bone, cementum, gingival submucosa, oral submucosa, tongue, and taste bud tissue. In a preferred embodiment, the oral tissue is a salivary gland. The phrase also refers to a portion of the oral tissue, such as a portion of a salivary gland.
[0082] The phrase "oral tissue construct" refers to a matrix, preferably a biocompatible matrix that has been seeded with oral tissue cells, wherein the cells have attached and filled the biocompatible matrix and grow, proliferate and differentiate on the matrix. The phrase also refers to a newly formed structure representing the early stages of oral tissue development.
[0083] The phrase "salivary gland construct" refers to a matrix, preferably a biocompatible matrix, that has been seeded with salivary gland cells, wherein the cells have attached and populated the biocompatible matrix and grow, proliferate and differentiate on the matrix. The phrase also refers to a newly formed structure that represents the early stages of salivary gland development.
[0084] The phrase "oral disease" refers to a disease or condition that affects the oral cavity. In particular, it refers to a disease or condition that affects saliva production. Examples of oral diseases include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjögren's syndrome, sialadenitis, mumps, sialoductitis, sialadenitis, salivary gland stones, sialolithiasis, mucocele, sublingual cyst, hyposecretion, sialorrhea, drooling, xerostomia, benign lymphoepithelial lesions of the salivary glands, salivary gland dilatation, salivary gland enlargement, salivary duct stenosis, and salivary duct stenosis.
[0085] The term "treatment" refers to treatment, prevention and preventive treatment, and particularly refers to the administration of a drug or medical procedure to a patient to preventively treat (prevent) or cure or reduce the extent or likelihood of a disorder or disease or condition or event. A treatment regimen using the agents described herein can be provided to stimulate or promote salivary gland regeneration and / or acinar cell replacement in the salivary glands.
[0086] The terms "individual," "subject," and "patient" are used interchangeably herein and refer to any member of the subphylum Chordata, including, but not limited to, humans and other primates, including non-human primates, such as chimpanzees and other apes and monkey species; livestock, such as cattle, sheep, pigs, goats, and horses; domestic mammals, such as dogs and cats; laboratory animals, including rodents, such as mice, rats, and guinea pigs; birds, including poultry, wild birds, and game birds, such as chickens, turkeys and other quail and gallinaceous birds, ducks, geese, etc. In some cases, the methods of the present invention can be used in experimental animals, veterinary applications, and the development of animal disease models, including, but not limited to, rodents, including mice, rats, and hamsters; primates, and transgenic animals.
[0087] A "therapeutically effective dose" or "therapeutic dose" refers to an amount sufficient to achieve a desired clinical outcome (ie, to achieve a therapeutic effect). A therapeutically effective dose can be administered in one or more administrations.
[0088] A "therapeutically effective dose or amount" of a composition comprising a cholinergic agonist (e.g., acetylcholine or carbachol) and / or a muscarinic agonist (e.g., cevimeline encapsulated in a hydrogel) means that when administered in the manner described herein, it is capable of producing a positive therapeutic response, such as improving the recovery of dry mouth. Improving recovery may include improving salivary gland function and increasing saliva production and salivary flow. In addition, a therapeutically effective dose or amount may stimulate the proliferation of acinar cells and acinar cell progenitor cells, resulting in repopulation of salivary glands and acinar cells. The exact amount required varies from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the specific drug used, the mode of administration, and the like. Based on the information provided herein, one of ordinary skill in the art can determine the "effective" amount appropriate in any individual case by routine experimentation. A therapeutically effective dose may be administered in one or more administrations.
[0089] The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce allergic or similar adverse reactions (eg, gastrointestinal upset, dizziness, etc.) when administered to humans (or, in the case of veterinary use, non-human animals).
[0090] Preferably, the term "pharmaceutically acceptable" as used herein refers to approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other generally recognized pharmacopoeia for use in animals, more specifically, in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or solvent with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or aqueous solutions saline solutions and aqueous dextrose and glycerol solutions are preferably used as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Encyclopedia by EW Martin.
[0091] "Pharmaceutically acceptable excipient" refers to an excipient that can be used to prepare a safe, non-toxic, intended pharmaceutical composition, including excipients acceptable for veterinary use as well as human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.
[0092] "Pharmaceutically acceptable salts" include, but are not limited to, amino acids, salts prepared with inorganic acids (e.g., chlorides, sulfates, phosphates, diphosphates, bromides, and nitrates), or salts prepared with the corresponding inorganic acid forms of any of the foregoing (e.g., hydrochlorides, etc.), or salts prepared with organic acids (e.g., malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, p-toluenesulfonate, pamoate, salicylate, and stearate, as well as propionate lauryl sulfate, glucoheptonate, and lactobionate). Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
[0093] The term "contrast agent" as used herein refers to a substance used to enhance the contrast of a target tissue, fluid or structure (e.g., salivary gland) in a subject in medical imaging. Exemplary contrast agents include, but are not limited to, ultrasound contrast agents (e.g., SonoVue microbubbles comprising sulfur hexafluoride, Optison microbubbles comprising an albumin shell and an octafluoropropane gas core, Levovist microbubbles comprising a lipid / galactose shell and an gas core, Perflexane lipid microspheres comprising perfluorocarbon microbubbles, Perflutren lipid microspheres comprising octafluoropropane encapsulated in a lipid shell), magnetic resonance imaging (MRI) contrast agents (e.g., gadodiamide, gadobenic acid, gadopentetate, gadoteridol, gadofosvesic, gadoversetamide, gadoxetate ) and radiocontrast agents, such as those used in computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iothalamic acid, iodoxylamic acid, ioglitic acid, etiobenzoic acid, iocabic acid, iodomethanesulfonate, iovodone, mepanemaglumine, iohexol, ioxanol, iopamidol, iopromide, iotrolan, ioversol, iopentol, iodixanol, iomeprol, iobitrol, ioxilan, ioxamic acid, iotosolic acid, iogancamic acid, cholinesterase, iobenzamic acid, iopanoic acid, iocetamol, iopamidol, sodium iopate, iobencarbamide, and calcium iopate).
[0094] Regenerate salivary glands by promoting acinar cell replacement
[0095] The present invention provides compositions and methods for regenerating salivary glands by promoting acinar cell replacement. Salivary gland regeneration may have the potential to permanently relieve dry mouth. The autonomic nervous system innervates the salivary gland acini, myoepithelial cells, vascular cells, and intercalated ductal cells. Salivary gland acinar cells secrete most of the fluid, electrolytes, and proteins in saliva. Neurotransmitter receptors are present on the basolateral membrane of acinar cells, which have α-adrenergic, β-adrenergic, M3 muscarinic, and cholinergic substance P receptors. The major pathway for protein exocytosis occurs through activation of β-adrenergic receptors (sympathetic pathway), while the major stimulus for fluid secretion occurs through activation of M3 muscarinic receptors (parasympathetic pathway).
[0096] The results showed that progenitor cells in adult salivary glands (including SOX2 +Acinar progenitor cells) are essential for the replenishment of acini and have an unexpected ability to repopulate tissue after radiation-induced injury. The results also found that cholinergic nerves play a critical role in controlling acinar cell replacement during homeostasis and that this neuronal influence can be replicated by adding cholinergic mimetics to acinar progenitor cells. Therefore, directly targeting acinar progenitor cells within tissue with cholinergic agonists and / or muscarinic agonists, or isolating and expanding acinar progenitor cells with cholinergic agonists and / or muscarinic agonists for transplantation and activation, can regenerate the secretory units of the salivary glands, thereby restoring functional salivary acini and treating oral diseases such as xerostomia after radiation therapy or xerostomia associated with Sjögren's syndrome. Given that organs such as the intestine, proventriculus, trachea, and taste buds that express SOX2 are heavily innervated by the autonomic nervous system and are damaged by therapeutic radiation used to eliminate cancer, such strategies may be applicable to the repair of multiple organ systems.
[0097] In some embodiments, a method for promoting salivary gland regeneration in a subject in need thereof comprises administering at least one of a cholinergic agonist or a muscarinic agonist to acinar progenitor cells of the salivary gland to promote acinar cell regeneration. The cholinergic agonist and / or muscarinic agonist can mimic the parasympathetic acetylcholine / muscarinic signaling that has been shown to maintain acinar cells in human salivary glands. In some embodiments, one or more cholinergic agonists and / or muscarinic agonists are topically administered to the salivary glands to promote acinar cell proliferation and increase saliva secretion.
[0098] In some embodiments, the acinar progenitor cells to which one or more cholinergic agonists and / or muscarinic agonists are administered include SOX2 + Acinar progenitor cells. SOX2 + Acinar progenitor cells may include AQP5 + / Ki67 + Cells and / or mucin (MUC) 19-cells. Exposure of endogenous acinar progenitor cells to cholinergic agonists and / or muscarinic agonists can cause the acinar progenitor cells to proliferate and develop into secretory acinar cells. Such treatment regimens can be used to repopulate the salivary glands with functional secretory acinar cells, for example, to treat subjects with oral diseases (e.g., salivary gland diseases) by restoring saliva flow. Subjects can be monitored for improvement of salivary gland diseases and saliva production and secretion after treatment.
[0099] In some embodiments, the cholinergic agonist may be selected from the group consisting of acetylcholine, bethanechol, carbachol, methacholine, arecoline, nicotine, galantamine, cevimeline, levamisole, muscarine, pilocarpine, donepezil, edrophonium, neostigmine, physostigmine, pyridostigmine, rivastigmine, tacrine, caffeine, huperzine, phosphocholine, isoflurane, cisapride, droperidol, domperidone, metoclopramide, risperidone and paliperidone. In other embodiments, the cholinergic agonist may include at least one of acetylcholine or an acetylcholine analog. For example, the acetylcholine analog may include carbachol.
[0100] In some embodiments, the muscarinic agonist may include an agonist that activates muscarinic acetylcholine receptors ("muscarinic receptors"). Muscarinic receptors are divided into five subtypes, referred to as M1-M5. Muscarinic agonists may include, but are not limited to, pilocarpine, aceclidin, xanomeline, talidine, sabcomeline, cevimeline, avameline, arecoline, mirameline, SDZ-210-086, YM-796, RS-86, CDD-0102A (5-[3-ethyl-1,2,4-oxadiazol-5-yl]-1,4,5,6-tetrahydropyrimidine hydrochloride), N-aryl urea substituted 3-morpholinoarecoline, VUO255-035 (N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3 -benzothiadiazole-4-sulfonamide), benzylquinolone carboxylic acid (BQCA), WAY-132983, AFB267B (NGX267), AC-42, AC-260584, chloropyrazines (including but not limited to L-687, 306, L-689-660, 77-LH-28-1, LY593039) and any quinuclidine ring with one or more carbon substitutions (especially including esters, sulfur or 5 or 6 carbon ring structures, including substituted nitrogen and / or oxygen) or any pharmaceutically acceptable salt, ester, analog, prodrug or derivative thereof. In some embodiments, a muscarinic agonist that is selective for the M1 and / or M3 muscarinic receptor subtypes (e.g., cevimeline) is used.
[0101] The cholinergic agonist and / or muscarinic agonist can be provided in the form of a pharmaceutical composition, which can be administered to acinar progenitor cells (including SOX2 + Acinar progenitor cells). The pharmaceutical composition can be formulated into a variety of dosage forms. The dosage can be a pharmaceutically or therapeutically effective amount that promotes acinar cell replacement and / or acinar progenitor cell maintenance and survival.
[0102] In various embodiments, the therapeutically effective doses of the cholinergic agonists and / or muscarinic agonists described herein can be present in different amounts. For example, in some embodiments, the therapeutically effective amount of the cholinergic agonist and / or muscarinic agonist can range from about 10-1000 mg (e.g., about 20 mg-1,000 mg, 30 mg-1,000 mg, 40 mg-1,000 mg, 50 mg-1,000 mg, 60 mg-1,000 mg, 70 mg-1,000 mg, 80 mg-1,000 mg, 90 mg-1,000 mg, about 10-900 mg, 10-800 mg, 10-700 mg, 10-600 mg, 10-500 mg, 100-1000 mg, 100-900 mg, 100-800 mg, 100-700 mg, 100-600 mg). g, 100-500mg, 100-400mg, 100-300mg, 200-1000mg, 200-900mg, 200-800mg, 200-700mg, 200-600mg, 200-500mg, 200-400mg, 300-1000mg, 300-900mg, 30 0-800mg, 300-700mg, 300-600mg, 300-500mg, 400mg-1,000mg, 500mg-1,000mg, 100mg-900mg, 200mg-800mg, 300mg-700mg, 400mg-700mg and 500mg-600mg). In some embodiments, the 15-PGDH inhibitor is present in an amount equal to or greater than about 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg. In some embodiments, the 15-PGDH inhibitor is present in an amount equal to or less than about 1000 mg, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg or 100 mg.
[0103] In other embodiments, the therapeutically effective dose of the cholinergic agonist and / or muscarinic agonist can be, for example, about 0.001 mg / kg body weight to 500 mg / kg body weight, such as about 0.001 mg / kg body weight to 400 mg / kg body weight, about 0.001 mg / kg body weight to 300 mg / kg body weight, about 0.001 mg / kg body weight to 200 mg / kg body weight, about 0.001 mg / kg body weight to 100 mg / kg body weight, about 0.001 mg / kg body weight to 90 mg / kg body weight, about 0.001 mg / kg body weight to 80 mg / kg body weight, About 0.001 mg / kg to 70 mg / kg body weight, about 0.001 mg / kg to 60 mg / kg body weight, about 0.001 mg / kg to 50 mg / kg body weight, about 0.001 mg / kg to 40 mg / kg body weight, about 0.001 mg / kg to 30 mg / kg body weight, about 0.001 mg / kg to 25 mg / kg body weight, about 0.001 mg / kg to 20 mg / kg body weight, about 0.001 mg / kg to 15 mg / kg body weight, about 0.001 mg / kg to 10 mg / kg body weight.
[0104] In another embodiment, the therapeutically effective dose of the cholinergic agonist and / or muscarinic agonist can be, for example, about 0.0001 mg / kg body weight to 0.1 mg / kg body weight, such as about 0.0001 mg / kg body weight to 0.09 mg / kg body weight, about 0.0001 mg / kg body weight to 0.08 mg / kg body weight, about 0.0001 mg / kg body weight to 0.07 mg / kg body weight, about 0.0001 mg / kg body weight to 0.06 mg / kg body weight, about 0.0001 mg / kg body weight to 0.05 mg / kg body weight. g / kg body weight, about 0.0001 mg / kg body weight to about 0.04 mg / kg body weight, about 0.0001 mg / kg body weight to 0.03 mg / kg body weight, about 0.0001 mg / kg body weight to 0.02 mg / kg body weight, about 0.0001 mg / kg body weight to 0.019 mg / kg body weight, about 0.0001 mg / kg body weight to 0.018 mg / kg body weight, about 0.0001 mg / kg body weight to 0.017 mg / kg body weight, about 0.0001 mg / kg body weight to 0.016 mg / kg body weight g body weight, about 0.0001 mg / kg to 0.015 mg / kg body weight, about 0.0001 mg / kg to 0.014 mg / kg body weight, about 0.0001 mg / kg to 0.013 mg / kg body weight, about 0.0001 mg / kg to 0.012 mg / kg body weight, about 0.0001 mg / kg to 0.011 mg / kg body weight, about 0.0001 mg / kg to 0.01 mg / kg body weight, about 0.0001 mg / kg to 0.009 mg / kg body weight weight, about 0.0001 mg / kg to 0.008 mg / kg body weight, about 0.0001 mg / kg to 0.007 mg / kg body weight, about 0.0001 mg / kg to 0.006 mg / kg body weight, about 0.0001 mg / kg to 0.005 mg / kg body weight, about 0.0001 mg / kg to 0.004 mg / kg body weight, about 0.0001 mg / kg to 0.003 mg / kg body weight, about 0.0001 mg / kg to 0.002 mg / kg body weight.
[0105] In some embodiments, the therapeutically effective dose can be 0.0001 mg / kg body weight, 0.0002 mg / kg body weight, 0.0003 mg / kg body weight, 0.0004 mg / kg body weight, 0.0005 mg / kg body weight, 0.0006 mg / kg body weight, 0.0007 mg / kg body weight, 0.0008 mg / kg body weight, 0.0009 mg / kg body weight, 0.001 mg / kg body weight, 0.002 mg / kg body weight, 0.003 mg / kg body weight, 0.004 mg / kg body weight. The effective dose of a particular individual can vary (e.g., increase or decrease) over time, depending on individual needs.
[0106] In some embodiments, the therapeutically effective dose of the cholinergic agonist and / or muscarinic agonist can be 10 pg / kg / day, 50 pg / kg / day, 100 pg / kg / day, 250 pg / kg / day, 500 pg / kg / day, 1000 pg / kg / day, or more. In various embodiments, the amount of the cholinergic agonist and / or muscarinic agonist is sufficient to provide a dose to a patient ranging from 0.01 pg / kg to 10 pg / kg, 0.1 pg / kg to 5 pg / kg, 0.1 pg / kg to 1000 pg / kg, 0.1 pg / kg to 900 pg / kg, 0.1 pg / kg to 900 pg / kg, 0.1 pg / kg to 800 pg / kg, 0.1 pg / kg to 700 pg / kg, 0.1 pg / kg to 600 pg / kg, 0.1 pg / kg to 500 pg / kg, or 0.1 pg / kg to 400 pg / kg.
[0107] Various embodiments may include different dosing schedules. In some embodiments, the cholinergic agonist and / or muscarinic agonist may be administered once every two months, once a month, twice a month, once every three weeks, once every two weeks, once a week, twice a week, three times a week, once a day, twice a day, or according to another clinically desirable dosing schedule. The dosing schedule for a single subject need not be at fixed intervals, but may vary over time, depending on the needs of the subject.
[0108] Based on the subject to be treated, the mode of administration, and the type of treatment desired (e.g., prevention, prophylactic treatment, treatment); the composition is formulated in a manner consistent with these parameters. A summary of such techniques is found in the latest edition of Remington's Pharmaceutical Compendium (Mack Publishing Co., Easton, Pennsylvania).
[0109] The preparation of therapeutic compositions containing small organic molecule polypeptides, analogs or active fragments as active ingredients is well known in the art. The compositions of the present invention can be administered parenterally, topically or through an implantable reservoir. Such compositions can be prepared as injections, which can be liquid solutions or suspensions; they can also be prepared as solid forms suitable for dissolving or suspending in liquids before injection. The preparations can also be emulsified. The active therapeutic ingredient is usually mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, etc. and combinations thereof. The preparations usually include diluents, and in some cases adjuvants, buffers, preservatives, etc. In addition, if necessary, the composition may contain a small amount of auxiliary substances, such as wetting agents or emulsifiers, pH buffers, which can enhance the efficacy of the active ingredient.
[0110] The composition can also be topically applied to the subject's site using a variety of techniques known to those skilled in the art. For example, these can include sprays, lotions, gels or other solvents, such as alcohols, polyethylene glycols, esters, oils and silicones. The compositions described herein can be pharmacokinetically and pharmacodynamically controlled by calibrating a variety of dosing parameters (including dosing frequency, dosage, duration mode and route). Changes in dosage, duration and mode of administration can also be manipulated to produce the desired activity. The therapeutic composition is usually administered in the form of a unit dose, for example, an intravenous unit dose. When used to indicate the therapeutic composition of the present invention, the term "unit dose" refers to a physically discrete unit suitable as a single dose for humans, each unit containing a predetermined amount of active substance calculated in combination with the necessary diluent (i.e., carrier) or solvent to produce the desired therapeutic effect.
[0111] The composition can be administered in a therapeutically effective amount in a manner compatible with the medicament, dosage form selected for treating the subject. If it is desired to obtain the desired effect in vitro, the effective amount of the cholinergic agonist and / or muscarinic agonist can range from about 0.1 nM to about 10 M, more preferably from about 0.1 nM to about 5 M, and most preferably from about 0.1 nM to about 1 M. The desired effect refers to the effect of the agent on promoting acinar cell replacement and / or acinar progenitor cell maintenance and survival. The exact amount of the active ingredient to be administered depends on the judgment of the practitioner and varies from person to person.
[0112] The agents described herein can be modified or formulated for administration to a pathological site. Such modifications can include, for example, formulating a formulation that improves or prolongs the half-life of the compound or composition, particularly in the environment. In addition, such modifications can include formulating the compound or composition to include a targeting protein or sequence that can promote or enhance the uptake of the compound / composition by acinar progenitor cells. In a specific embodiment, such modifications can cause the compound to preferentially target SOX2 in the salivary gland relative to other locations or cells. + Acinar progenitor cells.
[0113] The sterile injectable form of the composition can be an aqueous or oily suspension. The suspension can be prepared using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. The sterile injectable preparation can also be a sterile injectable solution or suspension placed in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile non-volatile oils are generally used as solvents or suspension media. For this purpose, any mild non-volatile oil can be used, including synthetic mono- or diglycerides. Fatty acids (such as oleic acid and its glyceride derivatives) can be used to prepare injectables, and natural pharmaceutically acceptable oils (such as olive oil or castor oil, especially its polyoxyethylated form) can also be used to prepare injectables. These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants (such as carboxymethyl cellulose or similar dispersants), which are generally used to prepare pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants (eg, Tweens, Spans and other emulsifying agents or bioavailability enhancers) that are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used in formulating the formulation.
[0114] Parenteral formulations may be a single bolus dose, an infusion or a loading bolus dose followed by a maintenance dose. These compositions may be administered once daily or "as needed". The pharmaceutical compositions may be administered orally in any orally acceptable dosage form, including capsules, tablets, aqueous suspensions or solutions. For oral tablets, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, useful diluents include lactose and dry corn starch. When an aqueous suspension is required for oral administration, the active ingredient is used in combination with an emulsifier and a suspending agent. Certain sweeteners, flavorings or coloring agents may also be added, if desired. Alternatively, the pharmaceutical compositions may be administered rectally in the form of suppositories. These may be prepared by mixing the medicament with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore melts in the rectum to release the drug. These substances include cocoa butter, beeswax and polyethylene glycol. The pharmaceutical compositions of the present invention may also be administered topically. Topical administration can be carried out in the form of rectal suppository formulations (see above) or suitable enema formulations. Local transdermal patches can also be used. For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing an active component suspended or dissolved in one or more carriers. Carriers for topical application of the compound of the present invention include mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing an active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0115] In some embodiments, the cholinergic agonist and / or muscarinic agonist can be formulated to control the release of the cholinergic agonist and / or muscarinic agonist to endogenous salivary gland acinar progenitor cells. The controlled release may include at least one of delayed release, sustained release, gradient release, time release, patterned release or spatial release. Delayed release, sustained release, gradient release, time release, patterned release or spatial release is a mechanism used in medicine that allows the release of active ingredients over time. The advantage of controlled release preparations is that they are delivered less frequently and have a defined release pattern compared to immediate release preparations of the same active compound.
[0116] Controlled release formulations can be designed to release active agents at a predetermined rate, thereby maintaining a constant level of agent over a specified extended period of time, such as at most about 1 hour, about 12 hours, about 24 hours, about 2 days, about 3 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks or longer after administration or after a lag period associated with delayed release of the agent. In certain embodiments, the active agent is released over a period of time, and the release time range is about 1 week to about 2 weeks or longer. Alternatively, the active agent can be released for at least 1 week, at least 2 weeks, at least 3 weeks or at most 14 days, at most 20 days, at most 30 days or longer. In other embodiments, the active agent is released in a time period of about 1 week to about 3 weeks or longer after administration.
[0117] In other embodiments, the cholinergic agonist or muscarinic agonist is provided in a biocompatible carrier, matrix or scaffold that can be administered to a subject. For example, the biocompatible matrix can include a polymer macroscaffold or microscaffold and at least one carrier material bound to or within the polymer macroscaffold or microscaffold. The at least one carrier material, matrix or scaffold can include a material capable of carrying and releasing at least one cholinergic agonist or muscarinic agonist to endogenous salivary gland acinar progenitor cells in a differential manner and / or in a controllable manner.
[0118] The carrier, matrix or scaffold can be any material that allows for the incorporation of cholinergic agonists and / or muscarinic agonists and can be combined with the expanded acinar progenitor cells (e.g., SOX2 + The carrier, matrix or scaffold is mainly non-immunogenic and biodegradable. Examples of biodegradable materials include, but are not limited to, alginate, polyglycolic acid (PGA), polylactic acid (PLA), hyaluronic acid, gut suture material, gelatin, cellulose, nitrocellulose, collagen, albumin, fibrin, cotton or other naturally occurring biodegradable materials. It may be preferred to sterilize the matrix or scaffold material prior to administration or implantation, for example, by treating it with ethylene oxide or by gamma irradiation or electron beam irradiation. In addition, many other materials can be used to form the scaffold or framework structure, including but not limited to: nylon (polyamide), Dacron (polyester), polystyrene, polypropylene, polyacrylates, polyvinyl compounds (such as polyvinyl chloride), polycarbonate (PVC), polytetrafluoroethylene (PTFE, Teflon), thermanox (TPX), hydroxy acid polymers (such as polylactic acid (PLA), polyglycolic acid (PGA) and polylactic-glycolic acid (PLGA)), polyorthoesters, polyanhydrides, polyphosphazenes, and various polyhydroxyalkanoates and combinations thereof.
[0119] Suitable matrices include polymeric nets or sponges and polymeric hydrogels. Hydrogels are defined as substances formed when (natural or synthetic) organic polymers are cross-linked by covalent, ionic or hydrogen bonds to form a three-dimensional open lattice structure to capture water molecules to form a gel. Typically, these polymers are at least partially soluble in aqueous solutions (e.g., water, buffered saline solutions, or aqueous ethanol solutions with charged side groups) or their monovalent ionic salts.
[0120] In certain embodiments, the matrix can be less than one year, more preferably less than six months, most preferably in a period of two to ten weeks to achieve biodegradation. The polymer composition and the manufacturing method can be used to determine the degradation rate. For example, more amounts of polylactic acid are mixed with polyglycolic acid to shorten the degradation time. Useable polyglycolic acid nets are commercially available, for example, obtained from surgical supply companies (e.g., Ethicon, New Jersey).
[0121] For example, a muscarinic agonist can be encapsulated in an alginate hydrogel. In some embodiments, the encapsulated muscarinic agonist is selective for M1 and / or M3 muscarinic receptor subtypes (e.g., Cevimeline). In other embodiments, the muscarinic agonist is a non-selective muscarinic agonist (e.g., Pilocarpine). The alginate in the hydrogel can be ionically cross-linked with divalent cations (see, e.g., Example 2, for description of biodegradable cross-linked calcium alginate hydrogels encapsulating Cevimeline). In some embodiments, the concentration range of the alginate in the hydrogel is from about 2wt% to about 10wt% (percentage by weight), including any wt% within the range, e.g., 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10wt%. In some embodiments, the alginate is partially oxidized. For example, about 2% to about 10% of the alginate can be oxidized, including any percentage within this range, such as 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5% or 10%. In one embodiment, about 2% of the alginate in the hydrogel is oxidized, and the concentration of the alginate is 5wt%. Such alginate hydrogels are capable of continuously delivering muscarinic agonists for at least 7 days after administration to a subject (see, e.g., Example 2)
[0122] Compositions comprising encapsulated cholinergic agonists and / or muscarinic agonists suitable for local delivery to salivary glands. The physician can locate the salivary glands to be injected, for example, by palpation or medical imaging (e.g., ultrasound, radiography, or MRI). In some embodiments, a contrast agent is included in the composition comprising the encapsulated cholinergic agonist and / or muscarinic agonist so that the positioning of the composition relative to the salivary glands is confirmed by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., suitable for ultrasound imaging) or a radiopaque contrast agent (e.g., suitable for radiography). The contrast agent can be included in the same composition or a different composition with the cholinergic agonist and / or muscarinic agonist and used before or after administration of the cholinergic agonist and / or muscarinic agonist.
[0123] In certain embodiments, the composition is injected into or adjacent to the salivary gland.Salivary glands that may be treated by the subject method include, but are not limited to, parotid, submandibular, and sublingual glands, and minor salivary glands, including serous, mucous, or seromucous salivary glands.
[0124] In certain embodiments, the subject being treated suffers from an oral disease, such as a disease that affects saliva production. Examples of oral diseases include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjögren's syndrome, sialadenitis, mumps, sialoductitis, sialadenitis, salivary gland stones, sialolithiasis, mucocele, sublingual cyst, hyposecretion, sialorrhea, drooling, xerostomia, benign lymphoepithelial lesions of salivary glands, salivary gland dilatation, salivary gland enlargement, salivary duct stenosis, and salivary duct stenosis. In other embodiments, the subject may have previously received radiation therapy that can cause xerostomia. The methods described herein can be used to treat such oral diseases (i.e., xerostomia) that affect saliva production suffered by human subjects. The methods described herein will also be used in veterinary applications to treat xerostomia such as suffered by domestic animals, including but not limited to pets (e.g., dogs and cats) and livestock (e.g., sheep, goats, pigs, horses, and cattle).
[0125] Reagent test kit
[0126] The present invention also provides a kit for treating dry mouth suffered by a subject with at least one of a cholinergic agonist or a muscarinic agonist to promote acinar cell generation. The cholinergic agonist and / or the muscarinic agonist may be contained in a separate composition or in the same composition. The kit may include a unit dose preparation containing a cholinergic agonist and / or a muscarinic agonist suitable for use in the treatment methods described herein, such as an injectable dose. In such a kit, in addition to the container containing the unit dose, there is also a drug instruction sheet describing the use and concomitant benefits of the treatment of dry mouth. The kit may include, for example, a dosing regimen for the cholinergic agonist and / or the muscarinic agonist included in the kit.
[0127] Of particular interest are formulations suitable for topical administration to the salivary glands, and in such embodiments, the kit may further include one or more syringes or other devices to accomplish such administration. In some embodiments, the kit includes a first syringe or device pre-loaded with a composition (e.g., a muscarinic agonist, e.g., encapsulated in an alginate hydrogel, which may be stored frozen). The kit may further include a second syringe containing calcium chloride, which may be connected to the first syringe via a Luer lock. For example, the first syringe may be injected into the salivary glands by thawing the contents of the first syringe (e.g., Cevimeline encapsulated in an alginate hydrogel) and mixing them with the contents of the second syringe (e.g., CaCl 2 The kit is used by mixing the salivary glands to be injected, for example, by palpation or ultrasound imaging.
[0128] In some embodiments, the kit further comprises a contrast agent to confirm the localization of the composition comprising the muscarinic agonist (e.g., cevimeline encapsulated in an alginate hydrogel) relative to the salivary gland by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., suitable for ultrasound imaging) or a radiopaque contrast agent (e.g., suitable for radiography). The contrast agent can be included in the same composition or a different composition as the muscarinic agonist and added before or after administration of the muscarinic agonist.
[0129] In addition to the above components, the target kit may further include (in certain embodiments) instructions for implementing the target method. These instructions may be present in the target kit in various forms, one or more of which may be present in the kit. One form in which these instructions may exist is printed information on a suitable medium or substrate (e.g., a sheet or sheets of paper with information printed thereon), a kit package, a package insert, etc. Another form in which these instructions exist is a computer-readable medium with information recorded thereon, such as a floppy disk, a compact disk (CD), a portable flash drive, etc. Another form in which these instructions may exist is a website, whereby information on a remote website can be accessed via the Internet.
[0130] Other embodiments described herein will be apparent to those skilled in the art in view of the specification and practice of the invention disclosed herein. For whatever reason, all U.S. patents and other references mentioned herein are expressly incorporated herein by reference. The specification and examples should be regarded as exemplary only, and the true scope and spirit of the invention are indicated by the following claims.
[0131] experiment
[0132] The following examples are presented to fully disclose and describe the methods of making and using the present invention to those of ordinary skill in the art, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the following experiments are all or the only experiments performed. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure refers to atmospheric pressure or near atmospheric pressure.
[0133] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0134] In order to include preferred embodiments of the present invention, the present invention has been described according to specific embodiments found or proposed by the inventors. It will be appreciated by those skilled in the art that, based on the disclosure of the present invention, various modifications and changes may be made to the specific embodiments listed without departing from the intended scope of the present invention. For example, due to codon redundancy, the potential DNA sequence may be changed without affecting the protein sequence. In addition, for consideration of biological functional equivalence, the structure of the protein may be changed without affecting the type or quantity of the biological action. All of these modifications are included within the scope of the appended claims.
[0135] Example 1
[0136] Salivary gland acini regenerate in response to cholinergic activation after radiation therapy via a progenitor cell-dependent mechanism
[0137] introduce
[0138] Therapeutic radiotherapy remains a life-saving treatment for cancer patients and is used to treat a range of malignancies, including head and neck cancer. In fact, the vast majority of patients with head and neck cancer receive radiotherapy in addition to chemotherapy and surgery (approximately 60,000 new patients per year in the United States; Siegel et al., 2015). Although this combined treatment approach is highly effective in eliminating tumors, it can induce severe side effects that damage and / or destroy healthy tissues located in the irradiated area. These organs include the salivary glands, which can show tissue dysfunction even after low-dose radiation therapy (Grundmann et al., 2009). At the higher doses (60 Gy) routinely given to patients, off-target radiation damages the acinar cells that synthesize saliva (Sullivan et al., 2005; Redman, 2008) and leads to lifelong dry mouth and comorbidities (e.g., dental caries, oral infections, impaired wound healing (Brown et al., 1975; Dreizen et al., 1977; Dusek et al., 1996)). Although IMRT has been successful in avoiding destruction of one of the three major salivary glands (the parotid gland), the proximity of the gland to the tumor often precludes the use of this technique, resulting in dry mouth syndrome in 80% of patients with head and neck cancer (Lee & Le, 2008).
[0139] As with all other organs damaged by radiation therapy, including the lungs, heart, and bladder (Emami et al., 1991), few treatment options are available to improve or restore tissue function. Current treatment options for cancer survivors with radiation-induced salivary gland dysfunction and degeneration focus on short-term symptom relief, but no long-term restorative therapies are available. Regenerative strategies, such as reactivating endogenous stem cells or transplanting non-irradiated stem cells, have been proposed (Lombaert et al., 2008; Ogawa et al., 2013; Pringle et al., 2016). However, these applications are limited by a lack of understanding of the properties of adult salivary gland progenitors that generate acini under homeostatic or injury conditions. Although it has recently been proposed that acinar cells are generated by self-replication rather than by definitive progenitors (Aure et al., 2015), the progenitor-like activity of these cell subsets has not been analyzed. It remains to be determined whether acinar cells, either through self-replication or through progenitor expansion, can repopulate cells after genotoxic insults. Although a number of studies have utilized irradiated salivary glands as a degeneration model (Zeilstra et al., 2000; Coppes et al., 2001, 2002), the in vivo regenerative capacity of adult salivary gland cells damaged by radiation therapy has not been investigated.
[0140] Little is also known about how acinar cells are replaced during salivary gland homeostasis. Studies on adult organs over the past 150 years have clearly demonstrated that peripheral nerves are essential for maintaining organ and tissue integrity (Erb, 1868). In the absence of motor neuron stimulation, skeletal muscle atrophies (Fu & Gordon, 1995; Batt & Bain, 2013), and epithelial organs such as fungiform taste buds (Von Vintschgau & Honigschmied, 1877), the prostate (Wang et al., 1991; Lujan et al., 1998), and salivary glands degenerate after sensory and / or autonomic nerve ablation (Schneyer & Hall, 1967; Mandour et al., 1977; Kang et al., 2010). Although it is unclear how nerves control tissue homeostasis in these organs, studies in the skin have shown that sensory nerves promote self-renewal of adult epithelial stem cells through sonic hedgehog secretion, thereby maintaining downstream cell lineages, i.e., dome cells in the skin (Peterson et al., 2015; Xiao et al., 2015). In addition, studies on salamanders (Wallace, 1972) and embryonic salivary glands (Knox et al., 2013) have shown that peripheral nerves have the ability to regenerate tissues by activating pluripotent stem cells, but corresponding evidence is lacking in adult mammalian systems.
[0141] Combining mouse genetics, ex vivo culture, and human tissue explants, we unexpectedly found that salivary gland acini are capable of regenerating after radiation therapy, in response to cholinergic activation through a progenitor cell-dependent mechanism. We demonstrate that SOX2 marks the only progenitor of the acinar lineage capable of replacing acinar cells during homeostasis and after radiation-induced injury, suggesting that salivary gland progenitors can withstand genotoxic shock, at least in the short term. Importantly, treatment of both healthy and irradiated tissue with a cholinergic mimetic stimulated acinar cell recruitment. Thus, our data demonstrate that tissues have extensive regenerative capacity even under genotoxic shock and suggest that targeting SOX2 may be a promising target for regenerative medicine. + The cells could be a therapeutic approach to regenerate tissue damaged by radiation therapy.
[0142] result
[0143] SOX2 marks progenitors that form acinar but not ductal cells during salivary gland homeostasis
[0144] SOX2 has been identified as a progenitor cell marker in the fetal mouse submandibular and sublingual salivary glands, but the expression of SOX2 in adult tissues is still unclear. +Whether SOX2 is expressed by acinar cell subsets in all three major adult salivary glands is unknown. Figure 1A , submandibular gland (SMG), sublingual gland (SLG), parotid gland (PG)]. In mice, SOX2 protein is restricted to adult mouse SLG (not found in SMG and PG, Figure 1B and 10A ), which is expressed by undifferentiated aquaporin (AQP) 5-positive, mucin (MUC) 19-negative acinar cells (accounting for all AQP5 + 21 ± 4% for acinar cells; Figure 1C and 1D ) expression. Consistent with their potential role as progenitor cells, about 6% of SOX2 + AQP5 + Cells co-expressing Ki67( Figure 1E and 10B ), while 19±4% of the cells were in the cell cycle (CyclinD1 + ; Fig. 10C ). In order to determine the + To determine whether cells commit to acinar and ductal lineages, we used the mTmG Sox2 reporter gene strain hybridization CreERT2 Mouse (Arnold et al., 2011) for genetic lineage tracing. mTmG The mouse is a dual fluorescent reporter mouse that, when crossed with the Cre strain, expresses membrane-targeted tandem dimer Tomato (mT) before Cre-mediated excision and membrane-targeted green fluorescent protein (mG) after excision ( Muzumdar et al., 2007 ; Fig. 10D ). Therefore, lineage-traced cells will express mG. Figure 1F As shown, SOX2 + Cells self-renew after 14 or 30 days and give rise to differentiated acinar cells marked by AQP5 and MUC19, but not KRT8 + Ductal cells ( Figure 1F and EV1E). Therefore, our lineage tracing results suggest that SOX2 + The cells are lineage-restricted progenitors that give rise to differentiated progeny, similar to what has been observed in the epidermis, intestine, and incisor (Owens & Watt, 2003; Barker, 2014; Seidel et al., 2017).
[0145] Given KIT +The cells are mainly found in the intercalated ducts of the SLG and SMG (Andreadis et al., 2006; Nelson et al., 2013) and have been proposed to give rise to acinar cells in adult tissues (Lombaert et al., 2008; Nanduri et al., 2013, 2014; Pringle et al., 2016). Therefore, we used 6-week-old Rosa26 mTmG Reporter Gene Hybridization Kit CreERT2 However, no KIT expression was evident in SLG or SMG 14 days or 6 months after induction. + Acinar cells of cell origin (i.e., double positive for AQP5 and mG) Fig.10F ). In contrast, KIT + Cells contributed exclusively to the intercalated ductules in the SLG (as observed by co-staining for the intercalated duct marker KRT8) and to the intercalated ductules and larger ductules in the SMG. Thus, these data suggest that KIT + Cells are ductal and of the acinar lineage SOX2 + Progenitor cells.
[0146] SOX2 and SOX2 + Cells are essential for the generation of secretory acini
[0147] Our lineage tracing analysis confirmed that SOX2 + cells give rise to acinar but not ductal cells. However, as we additionally observed, Ki67 + SOX2 - Acinar cells (about 6% SOX2 + Ki67 + and 16.5% SOX2 - Ki67 + cell, Fig. 10B )—indicating alternative progenitors or transit-amplifying cells of the acinar lineage, we characterized this by using Sox2 CreERT2 ;Sox2 fl / fl Mouse ( Figure 2A and 2C ) Genetically ablate SOX2 + Sox2 in cells, or using the inducible Sox2 promoter (Sox2 CreERT2 ;Rosa26 DTA ; Figure 2B and 2D ) ablation of SOX2 by diphtheria toxin (DTA) + Cells to study the maintenance and repair of SLG in SOX2 and SOX2 + In the latter assay, SOX2+ Cells undergo cell death in response to intracellular DTA production. + Sox2 in cells or elimination of Sox2 by DTA + Cells make SOX2 + and AQP5 + Cells (not KRT8 + ductal cells) are severely depleted, suggesting that Sox2 and SOX2 + Cells are necessary to maintain functional acini ( Figures 2A-2D ;Sox2 or SOX2 + The efficiency of cell ablation can be found in Fig.11A In the absence of Sox2, acinar cells, but not ductal cells, exit the cell cycle, as evidenced by cyclin D1 (CCND1). + The decrease in acinar cells is seen in Fig.11D ; Arrows indicate CCND1 + cells, white dashed lines highlight ductal cells). In addition, SOX2 + Ablation of cells resulted in almost no acini remaining on day 8 ( Figure 2B and 2D and 11A), which can be seen from the complete absence of AQP5 in large areas of the ductal network + This can be seen in the fact that the ducts are marked with dashed lines or KRT8, Figure 2B To exclude the possibility that tissue degeneration was entirely due to tissue instability rather than loss of acinar cell replacement, we examined the SLG after short-term ablation. As shown in Figure 8, on day 4 or 5 (3 or 4 days after tamoxifen treatment), Sox2 CreERT2 ;Sox2 fl / fl and Sox2 CreERT2 ;Rosa26 DTA Only a small amount of SOX2 is present in the SLG gland + cell( Fig. 8A and 8B ), Sox2 transcripts were significantly reduced ( Figure 8B ). The acini were disorganized and atrophic in appearance. In addition, we did not observe SOX2 + This suggests that SOX2 is not ectopically expressed in acinar cells in response to tissue injury. We also determined whether the changes in tissue composition were due to decreased levels of innervation, an important regulator of tissue function. CreERT2 ;Sox2 fl / fl Similar levels of innervation were measured in SLG as in wild-type controls, and Sox2 CreERT2 ;Rosa26DTA Axon bundles in SLG increased significantly ( Fig. 11B and 11C ). The latter finding suggests that cell ablation triggers the release of factors that promote innervation, but even if innervation levels increase, regeneration is not possible in the absence of SOX2+ cells. Together, these results suggest that SOX2 + cells, at least under the conditions tested, are the only acinar progenitors in the SLG, and acini are not generated by self-replication of fully differentiated acinar cells as previously proposed (Aure et al., 2015). Similar to studies in the epidermis, intestine, and incisor (Owens & Watt, 2003; Barker, 2014; Seidel et al., 2017), our data also suggest the presence of SOX2 + transiently amplifying populations of cells, which may be involved in rapidly repopulating the acinar compartment.
[0148] Parasympathetic protection of SOX2 + progenitor cells and promote SOX2-mediated acinar cell replacement
[0149] Adult rat and human salivary glands atrophy following elimination of parasympathetic activity. However, the effects of denervation on acinar cell replacement and progenitors have not been investigated (Garrett et al., 1999; Raz et al., 2013). To this end, we denervated one of the two rat SLGs by transection of the chorda tympani ( Figure 3A ; the contralateral gland was used as an internal control). After 7 days, the neuronal genes Tubb3, Vip, and Vacht ( Figure 3B , red column) and GFRa2 + or TUBB3 + nerve( Figure 3C and 12C ) transcript levels were severely reduced, indicating successful denervation. We did not observe a simultaneous loss of the cholinergic muscarinic receptor Chrm1 and Chrm3 transcripts ( Figure 3B , red bars); however, in the absence of parasympathetic innervation, a compensatory mechanism may be able to maintain transcription of Chrm1 and Chrm3. Although the SLG is primarily innervated by parasympathetic branches that are less innervated by sympathetic nerves (Emmelin et al., 1965), we did observe a decrease in sympathetic innervation after chorda tympani transection ( Fig. 12A ). Therefore, although sympathetic levels were low, we cannot exclude the possibility that some of the effects of denervation are due to loss of sympathetic input.
[0150] Similar to the effects of radiation therapy on tissue structure (Sullivan et al., 2005; Redman, 2008), adult acinar cells and SOX2 +Progenitor cells are more sensitive to loss of innervation than ducts. Denervation results in a decrease in acinar cell size (as previously observed; Patterson et al., 1975; Fig. 12B ) caused a decrease in the levels of AQP5 protein and transcripts of the differentiated acinar cell marker Muc19 ( Figure 3B and 3D Interestingly, MIST1 transcript and protein levels were unchanged after denervation ( Figure 3B , 3E and 3F), indicating that although functional markers of acinar cells are disrupted in the absence of innervation, the identity of acinar cells is not adversely affected. + Cells lose the ability to express Sox2 (using Sox2 eGFP mice), and the levels of SOX2 protein and transcripts were significantly reduced ( Figure 3B , 3C and 3F and 12C), indicating that denervation is required for SOX2 maintenance. + To determine whether cells were still able to repopulate tissues, we performed genetic lineage tracing in which cells expressing Sox2 were expressed under the control of the endogenous Sox2 promoter (Sox2 CreERT2 ;Rosa26 mTmG )-driven Cre was activated 3 days after denervation and tracked until day 14. Figure 3G and 3H As shown, 14 days after transection, Sox2 + Acinar cell replacement of progenitor cells was significantly reduced (-50%). Similarly, in SLGs induced to reprogram prior to nerve transection (for tamoxifen, 1 day before transection), SOX2 + Acinar cell replacement by progenitor cells was significantly depleted (~50%) after 14 days ( Fig.12E and 12F ). The reduction in acinar cell replacement may be due to reduced cell proliferation rather than cell death, as we measured a decrease in Ccnd1 but did not observe cell death markers [ Figure 12G CASP3 + ) cells or Fig.12H The absence of cell death also suggests that cells previously positive for SOX2 are still present, but cholinergic innervation is essential for maintaining SOX2 expression.
[0151] To confirm that denervation preferentially affects the acinar lineage in the SLG, we also analyzed other epithelial lineages.+ The ducts were similar to corresponding ducts in innervated controls, as were transcript levels of the ductal genes Krt7, Krt8, and Krt19 ( Figure 3B , 3D and 3F). In addition, progenitor cells in the developing SMG / SLG that are maintained by parasympathetic nerves (Knoxet et al., 2010) express KRT5 + cells (Knoxet et al., 2010; Lombaert et al., 2013) are not affected by denervation ( Figure 3F and 12; for expression of transcript Krt5, see Figure 3B Based on these findings, we conclude that parasympathetic innervation is required for adult SLG tissue homeostasis, regulating SOX2 and SOX2 + Cells preferentially maintain and replace functional acini.
[0152] To determine whether reinnervation of salivary glands with nerves could rescue acini and SOX2, we examined mouse salivary glands 30 days after denervation. Due to the plasticity of the peripheral nervous system, mouse salivary glands can re-innervate over time, as shown by the expression of TUBB3 at 30 days after transection. + Reappearance of nerves Fig.9A ) and re-expression of the neuronal genes Tubb3, Vip, and Vacht ( Figure 3B , blue columns; Yawo, 1987). Surprisingly, we found that the expression of these neuronal genes increased at day 30 ( Figure 3B )—indicating hyperinnervation in response to the original injury. Notably, after reinnervation, the levels of Sox2 and Aqp5 transcripts and SOX2 protein, as well as SOX2 + and AQP5 + The number of cells and the size of acinar cells were restored to or above the control level ( Figure 3B and 9A -9C).
[0153] To ensure SLG's SOX2 + Cells can directly respond to acetylcholine produced by parasympathetic nerves, and we analyzed SOX2 + Cellular expression of acetylcholine / muscarinic receptors in vivo and their responsiveness to muscarinic agonists. SOX2 + The cells expressed CHRM1 and CHRM3 (95% and 99%, respectively; Figure 4A and 4B ), wild-type mice were short-term treated with the muscarinic agonist pilocarpine (administered intraperitoneally and sacrificed at 18 hours) to induce proliferation of SOX2 + Cells (SOX2+ Ki67 + cell; Figure 4C and 4D ) percentage increase. However, SOX2 + There was no significant change in the percentage of cells 18 hours after injection ( Figure 4D ), indicating that muscarinic activation does not induce ectopic expression of SOX2. Therefore, these data support our hypothesis that parasympathetic nerves maintain SOX2 expression through acetylcholine-type muscarinic signaling. + progenitor cells and acini and promotes the recruitment of acinar cells.
[0154] Murine salivary gland regenerates after radiation-induced damage via SOX2
[0155] The murine salivary gland (primarily the SMG) has been extensively used to study the effects of ionizing radiation (IR) on gland function and structure, with analyses typically limited to degenerative responses. Loss of acinar cells and decreased salivary flow rates have been reported in the C57BL / 6 background strain following a single 10 Gy dose (Zeilstra et al., 2000; Coppeset et al., 2001, 2002). However, the regenerative capacity of the tissue and whether it remains innervated after IR is unclear. To test the effects of radiation on SOX2-mediated salivary gland regeneration, we analyzed innervation, SOX2 expression, and remodeling in the SLG of mice following a single dose of gamma irradiation to the head and neck. + Similar to previous studies in salivary glands (Avila et al., 2009), we found that a 10 Gy dose induced DNA damage and cell cycle arrest and reduced cell proliferation in SLGs on the first day after IR, as evidenced by a significant increase in the expression of the pro-apoptotic gene Bax and the cell cycle inhibitor Cdkn1a (p21) ( Fig.13A ) and decreased transcriptional levels of the cell proliferation marker Mki67 ( Fig.13A ). Then, we use TUBB3 + Nerve immunolabeling and semiquantitative PCR (qPCR) for Tubb3 and the parasympathetic nerve-derived neurotransmitter Vip were performed to measure changes in innervation and neural function in the IR SLG. Figure 5A and 5B As shown, TUBB3 in IR SLG + Neurons showed no changes compared to non-IR controls at 1 and 3 days after irradiation. However, transcript levels of Tubb3 and Vip were significantly reduced at 1 and 3 days after IR, suggesting that neuronal function was reduced at an early stage ( Fig. 13B ). Similarly, the transcript levels of Sox2, Mist1, and Aqp5 decreased immediately after IR but returned to control levels at day 7 after IR ( Fig. 13B ). On day 1 after IR, SOX2 + The number of cells decreased significantly ( Figure 5C ), while CCND1 + SOX2 + The number of cells increased significantly at 3 and 7 days after IR (5C). To determine whether SOX2-mediated cell replacement was affected after IR-induced injury, we analyzed the expression of Sox2 at 14 days after IR. CreERT2 ;Rosa26 mTmG Surprisingly, we found that acinar cells were recruited by SOX2 in the IR SLG. + Cell replacement (GFP + cells)—this was similar to the non-IR control and produced SOX2 + GFP + and SOX2-negative offspring ( Figure 5D , white arrows indicate SOX2-negative progeny), indicating the presence of transient amplifying cells that are no longer SOX2 + , but derived from SOX2 + In addition, SOX2 in IR SLG + The number of cells was similar to that of the control group on day 14 ( Figure 5D ). Thus, despite the initial loss of neural signaling, SOX2, and acinar cell markers, the acinar compartment can be remodeled by SOX2 following radiation-induced injury. + Cells are replenished.
[0156] Next, we tested whether SLG could regenerate after IR injury in the absence of Sox2. Figure 5E As shown, Sox2 CreERT2 ;Sox2 fl / fl Mice are unable to repopulate tissues with functional AQP5+ acini. Indeed, in the absence of Sox2, we observed a decrease in AQP5 compared to wild-type mice 14 days after IR. + Acinar cell loss and structural destruction ( Figure 5E ). This result further confirmed that Sox2 is essential for SLG regeneration after radiation-induced injury.
[0157] SOX2+ cells can respond to cholinergic mimetics to replenish irradiated salivary glands
[0158] Since our data suggest that cholinergic cues recruit acinar lineages in the SLG, we used our ex vivo lineage tracing model to determine if SOX2 +Whether cells can recruit acini in response to muscarinic activation in healthy and irradiated SLG. Fig. 6A and 6B As shown, GFP expression in healthy SLG tissues cultured with the acetylcholine analog carbachol (CCh) for 48 hours + Cloning increased. GFP + This increase in colonies was consistent with the proliferation of CCh-treated cells (Ki67 + Cells) increase related to ( Fig.13E In our IR model, 24 h before animals received a single dose of IR, Sox2 CreERT2 ;Rosa26 mTmG Induced recombination in mice ( Fig. 6A This time point was chosen because the lag time of tamoxifen-induced recombination in the mouse Cre strain was previously reported to be 12-24 hours (Nakamura et al., 2006). + Cells were labeled 24 hours after injection ( Figure 6B , see 0 hour panel). SLGs were collected within 1 hour after radiation exposure and cultured in vitro for 48 hours in the presence or absence of CCh. Figure 6B as well as Figure 6C As shown in the quantification results in Figure 2, GFP in IR SLG was upregulated compared with that in non-IR control. + More clones showed that IR activated SOX2 + This may be due to cholinergic signaling from remaining nerves, as IR explants cultured with the muscarinic receptor antagonist 4-DAMP showed acinar cell recruitment similar to that of non-IR cultured salivary glands ( Figure 6B and 6C Importantly, treatment of IR explants with CCh resulted in a decrease in GFP expression compared with IR treatment alone. + Cell increase ( Figure 6B and 6C , and 13C and 13D). Based on these data, we conclude that SOX2 + Cells are able to repopulate the IR SLG in response to muscarinic activation.
[0159] Acetylcholine / muscarinic signaling maintains SOX2 and the acinar lineage in human SGs
[0160] In humans, IR results in parasympathetic innervation (increased sympathetic innervation) in the SG ( Knox et al., 2013 ; Fig.14A ; GFRA2) and markers of acinar lineage (AQP3, MIST1, AMY1) but not ductal lineage (EGFR, KRT19) were irreversibly decreased compared with non-IR controls ( Fig. 7A ; IR delivered approximately 2 years prior to surgery, n=7 (IR) and 11 (non-IR). Lineage markers were confirmed in human tissue by immunofluorescence (SMG was used due to availability) ( Fig. 14B In addition, we found that the transcript levels of SOX2, GFRA2, CHRM1, and CHRM3, but not tyrosine hydroxylase (TH, a sympathetic nerve marker), were also significantly downregulated or tended to be downregulated after IR ( Fig. 7A and 14A ), indicating that parasympathetic function and the ability of cells to respond to acetylcholine are exhausted. Therefore, we hypothesized that the loss of regenerative capacity of human salivary glands after IR is due to the loss of SOX2 + The authors hypothesized that SOX2 expression is sufficient to maintain the acinar lineage in response to reduced levels of parasympathetic innervation of progenitor cells and that acetylcholine / muscarinic signaling is sufficient to maintain SOX2 expression and promote the acinar lineage. To test this hypothesis, we established a novel human explant-murine nerve co-culture system. In this model, non-irradiated human SMGs were dissected into fragments <1 mm and placed next to embryonic day 13 murine submandibular gland parasympathetic ganglia (containing mesenchyme) or mesenchyme alone (control, no nerves). The tissues were then co-cultured on filters floating on serum-free medium for 7 days. Nerves migrated in and around the tissue ( Figure 7B ), and actively maintains tissue architecture, as evidenced by the fact that CDH1 (E-cadherin, gene and protein expression) levels were higher in explants co-cultured with nerves compared with mesenchyme alone ( Figure 7C and 7D We analyzed explants for the neural attractants neurotrophin (NRTN) and nerve growth factor (NGF) (Knox et al., 2013) in an attempt to identify factors that induce this neural migration. However, we found no increase in expression in the presence of ganglia compared to mesenchyme alone ( Fig.7D ), suggesting that other neural attractants are being synthesized and that the epithelium produces them with or without nerves (i.e., mesenchyme is sufficient to maintain epithelial homeostasis), or that this phenomenon occurs early in culture (i.e., it occurs at an early stage, when the nerves have just begun to wrap around the epithelium), and any differences are resolved by this later time point (day 7). Surprisingly, compared with controls with mesenchyme alone, glandular explants cultured with nerves had increased transcript levels of SOX2 (approximately 1.8- to 2-fold), the acinar markers MIST1 and CD44, and the muscarinic receptor CHRM3 (also expressed by acinar cells; Giraldoet et al., 1988), but differences were found in the ductal genes KRT19, KIT, and EGFR ( Fig.7D , data normalized to mesenchyme only, n = 2 individuals). In addition, Ki67 +Epithelial cell proliferation, a marker of the presence of neurons, increases in the presence of Figure 7C and 14C Together, these data demonstrate that parasympathetic nerves are able to maintain SOX2 expression as well as acinar and ductal markers in human salivary glands.
[0161] To address whether acetylcholine / muscarinic signaling is sufficient to maintain acini and SOX2 in human salivary glands + To address this question, we performed muscarinic stimulation of non-irradiated human SMG or PG (both expressing SOX2) tissue explants in an in vitro system. Patient-derived human tissue from four different individuals (n=4) was cultured with CCh, resulting in a significant increase in the expression of SOX2, muscarinic receptors CHRM1 and CHRM3 (all expressed by adult acinar cells (Giraldo et al., 1988; Mei et al., 1990)), as well as AQP3, AQP5 (Gresz et al., 2001), and MIST1 within 4 hours of muscarinic stimulation ( Fig. 7E , n = 4, single data set see Fig.14D Although surgical denervation did not adversely affect Mist1 expression ( Figure 3B and 3E ), but muscarinic stimulation was sufficient to increase MIST1 in human cultures, suggesting that acetylcholine / muscarinic signaling may serve as a positive regulator of the secretory program, although not required for acinar cell identity. The differences in response between the four patient-derived samples may be due to differences in biological diversity between human patients, type of gland source (SMG and PG were used), and patient age (donor age ranged from 30 to 78 years). However, in all cases, we observed an increase in SOX2 and many acinar markers in the presence of CCh. Although we also measured an increase in KRT19 gene expression in response to CCh, other unique ductal markers EGFR, KRT7, and KRT8 remained unchanged, suggesting that ductal cells are generally unresponsive to muscarinic agonists ( Fig. 7E Given that nerves increase ductal genes in human salivary glands in coculture, nerves may produce other factors that induce ductal changes (compare Fig.7D and 7E ). Thus, neuronal acetylcholine / muscarinic signaling is sufficient to promote the acinar lineage and maintain SOX2 expression in adult salivary glands.
[0162] discuss
[0163] Our study found that SOX2 +Cells are essential for the replenishment of acini and have an unexpected ability to repopulate tissue after radiation-induced injury. We further demonstrate that cholinergic nerves play a critical role in controlling SOX2-mediated acinar cell replacement during homeostasis and that this neuronal influence can be replicated by adding cholinergic mimetics to irradiated tissue. Thus, contrary to the current consensus that murine salivary glands do not regenerate after radiation-induced injury (Zeilstra et al., 2000; Coppes et al., 2001, 2002), these data suggest that, at least in mice, salivary glands have extensive regenerative capacity after radiation-induced injury. Furthermore, we show that the acinar lineage (and SOX2) in human tissue is also responsive to cholinergic mimetics, targeting SOX2 + Cells and maintenance of cholinergic nerves may contribute to the restoration of functional salivary alveoli after radiation damage.
[0164] SOX2 plays an important role in organismal development and can regulate the homeostasis of epithelial tissues such as the stomach, trachea, and intestine (Arnold et al., 2011). Similar to the reduced homeostatic capacity of adult tracheal cells after Sox2 ablation (Que et al., 2009), we found that SOX2 was downregulated under homeostatic and injury conditions. + After Sox2 ablation in acinar progenitor cells, AQP5 + Acinar cell depletion. Interestingly, although there was some atrophy, we did not see increased cell death in the absence of Sox2, but there was a significant decrease in cycling acinar cells, suggesting that upon ablation, these cells exit the cell cycle and differentiate to generate dormant AQP5-deficient acinar cells. SOX2 + The dramatic loss of acini after cell ablation further confirms that these cells are the sole progenitors of the acinar lineage in the SLG and is consistent with a recent report showing that pancreatic acinar cells are not equally potent but contain subsets of progenitor cells (Wollny et al., 2016). Our results contrast with a recent report by Aure et al., 2015, which showed that salivary gland acinar cells are replenished by self-replication of mature cells rather than by differentiation of progenitor cells, similar to the situation for pancreatic β cells (Dor et al., 2004). The conclusion that tissue repopulation is due to self-replication of salivary gland acinar cells is based on the use of the inducible Mist1 promoter, which is expressed by all acinar cells, including SOX2. + MUC19 - Therefore, the cell subpopulations tracked after reconstitution may include progenitor cells; however, no analysis was performed to determine whether these subpopulations had stem cell characteristics.
[0165] As with all epithelial organs, peripheral nerves are required to maintain structural homeostasis in rodent and human salivary glands (Schneyer & Hall, 1967; Mandour et al., 1977; Wang et al., 1991; Fu & Gordon, 1995; Lujan et al., 1998; Kang et al., 2010; Batt & Bain, 2013). During organogenesis, parasympathetic nerves maintain a progenitor population that exerts its effects on the tissue after radiation injury via acetylcholine / muscarinic signaling (Knox et al., 2013). Although previous salivary gland denervation studies have shown a reduction in organ and acinar cell size (Schneyer & Hall, 1967; Mandour et al., 1977; Kang et al., 2010), it was unclear whether nerve innervation is required for acinar cell replacement. Our studies demonstrate that nerves directly regulate SOX2 to drive acinar cell replacement from lineage-restricted progenitors. This result is consistent with the known role of SOX2 in regulating self-renewal and cell fate in many other organs (Arnold et al., 2011). However, to date, only cell-intrinsic signaling pathways, including those mediated by the WNT, FGF, and EGFR families, have been shown to regulate SOX2 (Hashimoto et al., 2012; Dogan et al., 2014; Rothenberg et al., 2015; Lee et al., 2016). This extrinsic nerve-based model has a clear advantage over cell-intrinsic signaling in that, unlike their target organs, neurons themselves are relatively resistant to radiation damage (Tofilon & Fike, 2000; Wong & Vander Kogel, 2004). It remains to be tested whether this mechanism also regulates the maintenance of other epithelial organs that express SOX2, such as taste buds (Suzuki, 2008), prostate and seminal vesicles (Wanigasekara et al., 2004), stomach (Tatsuta et al., 1985; Zhao et al., 2014), and cornea (Ueno et al., 2012). However, these results suggest that cholinergic nerves may play a role in the regeneration of these tissues.
[0166] Previous studies have utilized the murine salivary gland as a model of radiation-induced degeneration (Zeilstra et al., 2000; Coppes et al., 2001, 2002). These studies were based on the hypothesis that regenerative capacity is impaired after moderate to high doses of radiation, a hypothesis supported by the fact that salivary flow is reduced in irradiated animals (Redman, 2008). However, to date, in vivo analyses of cellular replacement after radiation have not been performed. Our data indicate that, at least during the first 30 days after radiation exposure, murine acinar cells are highly regenerative and are able to repopulate acini like uninjured controls. However, it is clear that this regenerative capacity cannot be maintained long-term, as murine salivary glands undergo degeneration / senescence 3–6 months after radiation (Urek et al., 2005; Marmary et al., 2016). Therefore, SOX2 + It is likely that the cells' regenerative capacity eventually fails, and further analysis is needed to understand why. Can human salivary glands regenerate within days / months after therapeutic radiotherapy, and whether this regenerative capacity is affected by SOX2? + The long-term failure of these cells and parasympathetic nerves in response to radiation injury remains to be determined. Indeed, the time course of changes in salivary glands in patients needs to be analyzed to understand how these organs are affected in the short and long term. However, our results suggest that targeting these stem cells and their innervating nerves to control and maintain tissue regeneration in response to radiation injury may potentially provide a means of maintaining / repairing tissue in the long term.
[0167] Several recent studies have aimed to address the issue of gland regeneration after radiation injury in mouse models by isolating putative stem cell populations for reimplantation (Nanduri et al., 2013, 2014) or preserving regions within the gland that are thought to harbor stem cells (van Luijk et al., 2015). However, it is still unclear what the identity of these endogenous stem cells is and whether they contribute to the acinar cell compartment. Furthermore, the effects of such manipulations on salivary gland innervation have not been reported. Based on our studies, the unexpected increase in innervation capacity due to tissue perturbation could allow SOX2 to function. + Progenitor cells are maintained and expanded, and these progenitor cells can regenerate the acini to restore salivary gland function. Xiao et al. (2014) reported restoration of rat salivary gland function and structure after radiation-induced damage by adding glial-derived neurotrophic factor (GDNF), a neuroattractant factor (Knox et al., 2013). However, a recent study showed that GDNF itself could not directly protect SG stem cells from radiation-induced damage (Peng et al., 2017), suggesting that this result may be a result of supporting niche improvement.
[0168] In conclusion, our studies highlight the extensive regenerative capacity of the salivary glands through the expansion and differentiation of progenitor cell populations, even in the face of genotoxic shock. Based on these data, we propose that direct targeting of SOX2 within the tissue + By isolating and expanding these cells for transplantation and activation, we may be able to regenerate the secretory units of the salivary glands and restore the patient's quality of life. As previously suggested (Knox et al., 2013), this also requires the maintenance of parasympathetic function to maintain SOX2 + Given that organs such as the intestine, proventriculus, trachea, and taste buds that express SOX2 are heavily innervated by the autonomic nervous system and are damaged by therapeutic radiation used to eliminate cancer, such strategies may be applicable to repair multiple organ systems.
[0169] Materials and methods
[0170] Mouse strains
[0171] All procedures were approved by the UCSF Institutional Animal Care and Use Committee (IACUC) and adhered to the NIH Guide for the Care and Use of Laboratory Animals. Mouse alleles used in this study were provided by Jackson Laboratory, including Sox2 eGFP (Arnold et al., 2011), Sox2 CreERT2 (Smith et al., 2009), Sox2 fl / fl (Taranova et al., 2006), Rosa26 mTmG (Muzumdaret et al., 2007), Rosa26 DTA (Wu et al., 2006) and Kit CreERT2 (Klein et al., 2013).
[0172] Animal experiments
[0173] Adult female mice (6 to 8 weeks of age) were used in all experiments unless otherwise stated. Mice were maintained at the AAALAC-accredited Laboratory Animal Resource Center (LARC) at the UCSF Parnassus campus. Mice were housed in individually ventilated cages (IVCs) with access to fresh water, regularly cleaned cages, and environmental enrichment, with a maximum of 5 mice per cage when possible. A power calculation was used to calculate the appropriate sample size. For transgenic studies, sample size was limited by the time required to breed sufficient animals of the desired genotype and sex. Wild-type animals were randomly assigned to experimental groups using Microsoft Excel software. Transgenic animals were assigned to groups based on genotype. All animals were given a unique ID number so that investigators were blinded during the analysis.
[0174] sox2 or sox2 + Gene ablation of cells
[0175] Conditional ablation of Sox2 was performed by daily infusion of Sox2 for four consecutive days before euthanasia on day 18. CreERT2 ;Sox2 fl / fl :R26 mTmG Mice were injected with 2.5 mg / 20 g tamoxifen and then injected with 2.5 mg / 20 g tamoxifen every three days. + Cells were ablated by daily expression of Sox2 for four consecutive days before euthanasia on day 7. CreERT2 ;Rosa26 DTA :R26 mTmG Mice were injected with 2.5mg / 20g tamoxifen. Rosa26 mTmG The mouse provides a valuable tool for lineage tracing combined with cell ablation / recombination (Muzumdar et al., 2007). Briefly, the model consists of a dual fluorescent Cre reporter that expresses membrane-targeted tandem dimer Tomato (mT) before Cre-mediated excision and membrane-targeted green fluorescent protein (mG) after excision ( Fig. 10D ). Thus, in these mice, cells that undergo recombination and therefore lack Sox2 or express DTA will express GFP. Endogenous GFP was imaged in experiments using cryosections, and a GFP antibody was used for paraffin-embedded tissues (chicken anti-GFP; 1:500, Aves Labs, GFP-1020).
[0176] SOX2 + Cell lineage tracing
[0177] Sox2 CreERT2 ;Rosa26 mTmG Mice were injected with 2.5 mg of tamoxifen and euthanized 24 h, 14 days, or 30 days later.
[0178] KIT+ cell lineage tracing
[0179] Kit CreERT2 ;Rosa26 mTmG Mice were injected with 2.5 mg of tamoxifen and euthanized 14 days or 6 months later.
[0180] In vivo denervation experiments
[0181] Administer C57BL / 6 or Sox2 30 min before surgery eGFPMice were given analgesics (carprofen and buprenorphine; Patterson Veterinary and Buprenex; 0.1 and 100 mg / kg (IP), respectively) and maintained in 2% isoflurane / O 2 The mixture was used for anesthesia. The surgical area was shaved and prepared for an incision, cleaned alternately with iodine and alcohol, and then a local anesthetic (lidocaine; Hospira Inc., 8 mg / kg) was applied. As described in previous studies (Klimaschewski et al., 1996), an incision was made in the ear and anterior to the chorda tympani, and a complete transect was made using spring scissors. The skin was sutured using non-absorbable suture silk (Ethicon) and the wound was further covered with surgical adhesive (Vetbond). The contralateral nerve was kept intact as a control. Mice were euthanized after 7 or 30 days.
[0182] Pilocarpine experiment
[0183] Adult male C57BL / 6 mice (6 to 8 weeks old) were dosed with pilocarpine (Sigma-Aldrich, P0472; 0.68 mg / ml, dissolved in 0.9% sterile saline). Mice were anesthetized with isoflurane and injected intraperitoneally with 4.5 mg / kg body weight (200 μl) of pilocarpine or 0.9% saline as a vehicle control. Mice were euthanized 18 hours later and glands were analyzed by immunofluorescence.
[0184] Gamma radiation experiments
[0185] C57BL / 6 mice were anesthetized with 1.25% 2,2,2-tribromoethanol (Alfa Aesar) dissolved in 0.9% saline (Vedco Inc.). 137 Cs irradiator (JL Shepherd & Associates) was used 137 The mice were irradiated with a Cs source. Two lead blocks 1.5 cm apart were used to protect the body and the front part of the mouth (nose and mouth) of the mice, exposing only the neck and part of the head. The 1.5 cm opening was located at the center of position 3 ( 137Cs source 20cm, 15.5cm from the edge of the irradiator chamber). The mice were irradiated with a radiation dose rate of 167Rads / min twice with a dose of 5Gy for 2.59 minutes (once on each side of the head, bilaterally, consecutively but on the same day) for a total dose of 10Gy to irradiate the salivary glands. This dose was calculated from the isodose map (dose distribution) provided by the manufacturer, and the 100% exposure area was located using EBT film (Brady et al., 2009) for the placement of mice. Control mice were anesthetized in the same manner as the experimental mice, but no radiation therapy was performed. All mice were allowed to fully recover before returning to their normal housing environment and were allowed to receive soft food (ClearH2O) ad libitum. 2 O). Mice were euthanized after 1 hour or 1, 3, 7, 14, or 30 days.
[0186] Organ culture experiments
[0187] Ex vivo lineage tracing of adult salivary glands
[0188] Sox2 CreERT2 ;Rosa26 mTmG Mouse salivary glands (24 hours before recombination induction) were mechanically cut into <1 mm fragments and then placed in complete medium (with or without 200 nM CCh (Sigma-Aldrich) or 10 μM 4-DAMP (Tocris)) for 48 h before fixation for immunofluorescence analysis. In some cases, mice received three 5 Gy doses of irradiation before the glands were cultured as above.
[0189] Isolation and culture of human salivary gland tissue
[0190] Adult salivary glands were obtained from discarded, de-identified tissues with consent from patients (28–78 years, males and females) undergoing neck resection. Informed consent was obtained from all subjects, and the experiments were conducted in accordance with the principles set forth in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Patients had not received radiation therapy (non-IR) or fractionated radiation therapy (IR) within 2 years prior to surgery. Tissues were immediately placed in 4% PFA, RNAlater (Qiagen), or DMEM (Thermo Fisher) for live cell explant culture. For ex vivo culture, non-IR tissues were dissected into <1 mm fragments and then cultured in serum-free DMEM / F12 containing holo-transferrin and ascorbic acid. For explant assays, tissues (SMG and PG) were incubated with 50–200 nM CCh (200 nM CCh is shown in the results) for 4 h before lysis for RNA. For salivary gland explant-parasympathetic submandibular ganglion (SMG) co-cultures, tissues were dissected into <1 mm fragments and cultured on floating filters above serum-free medium. E13 mouse parasympathetic submandibular ganglia were isolated as previously described (Knoxet et al., 2010). One parasympathetic submandibular ganglion per explant was placed next to a human salivary gland and cultured for 7 days before being fixed for immunofluorescence analysis or lysed for RNA.
[0191] Tissue processing
[0192] After fixation, salivary glands (human and mouse) were processed for OCT or paraffin embedding. To obtain frozen sections, tissues were incubated in increasing concentrations of sucrose (25-75%) and embedded in OCT. 12-μm sections were cut using a cryostat (Leica) and stored at -20°C. Tissues were dehydrated by incubation in increasing concentrations of ethanol followed by Histo-Clear (National Diagnostics) prior to embedding in paraffin (Sigma-Aldrich) for paraffin processing. 12-μm sections were cut using a microtome (Leica) and stored at room temperature.
[0193] Immunofluorescence analysis
[0194] Immunofluorescence analysis of whole-mount salivary glands and tissue sections has been described previously (Knox et al., 2010). Briefly, tissues were fixed with ice-cold acetone / methanol (1:1) for 1 min or 4% PFA for 20-30 min, followed by permeabilization with 0.1-0.3% Triton X. Tissues were blocked overnight at 4°C with 10% donkey serum (Jackson Laboratories, Maine), 1% BSA (Sigma-Aldrich), and MOM IgG blocking solution (Vector Laboratories, California) in 0.01% PBS-Tween 20. Salivary glands were incubated with the following primary antibodies overnight at 4°C: goat anti-SOX2 (1:200, Neuromics, GT15098); goat anti-SOX10 (1:500, Santa Cruz Biotechnology, sc-17342); mouse anti-TUBB3 (TUJ1 clone, 1:400, R&D Systems, MAB1195); goat anti-GFRa2 (1:100, R&D Systems, AF429); rabbit anti-tyrosine hydroxylase (1:100, Millipore, AB152); rat anti-E-cadherin (1:300, LifeTechnologies, 13-1900); rabbit anti-EGFR (1:200, Abcam, ab52894); rabbit anti-KRT5 (1:1,000, Covance, PRB-160P); rat anti-KRT8 (1:200, DSHB, Troma Biotechnology). I); mouse anti-KRT7 (1:50, Covance, MMS-148S); rat anti-CD44 (1:200, BioLegend, 103001); mouse anti-Ki67 (1:50, BD Biosciences, 550609); rabbit anti-CCND1 (1:200, Abcam, ab16663); rabbit anti-caspase-3 (1:100, Invitrogen, 34-1700); rabbit anti-AQP3 (1:400, Lifespan Biosciences Inc., LS-B8185); rabbit anti-AQP5 (1:100, Millipore, AB3559); goat anti-MUC19 (1:200, Abcore, AC21-2396); mouse anti-aSMA (1:400, Sigma-Aldrich, C6198); chicken anti-GFP (1:500, Aves Labs, GFP-1020); rabbit anti-CHRM3 (1:1,000, Research and Diagnostics, AS-3741S); and rabbit anti-MIST1 (1:500, gift from Stephen Konieczny, Purdue University).Antibodies were detected using Cy2-, Cy3-, or Cy5-conjugated Fab fragment secondary antibodies (Jackson Laboratory), and cell nuclei were stained using Hoechst 33342 (1:1,000, Sigma-Aldrich). Fluorescence was analyzed using a Leica Sp5 confocal microscope and NIH ImageJ software.
[0195] Morphological analysis and cell counting
[0196] For immunofluorescence analysis (e.g., Figure 2D ), and cells positively stained with markers were counted using ImageJ. Acinar cell size was measured using ImageJ. All data were obtained from 3-5 fields / group, and each experiment was repeated 3 times. For nerve density analysis, immunofluorescence of the neural marker TUBB3 was analyzed, and the raw integrated density (shown as arbitrary units, AU) was calculated using ImageJ.
[0197] Quantitative PCR analysis
[0198] RNA was isolated from whole tissue using the RNAqueous Micro kit (Ambion). Total RNA samples were DNase treated (Ambion) using SuperScript reagent (Invitrogen, CA) prior to cDNA synthesis. SYBR green qPCR was performed using 5 ng (mouse) or 4-10 ng (human) cDNA and primers designed using Primer3 and Beacon Designer software or described on PrimerBank (pga.mgh.harvard.edu / primerbank / ). Melting curves and primer efficiency were determined as previously described (Hoffman et al., 2002). Gene expression was normalized relative to housekeeping genes S18 and S29 (Rps18 and Rsp29) or GAPDH (for mouse) and GAPDH (for human) and corresponding experimental controls. Reactions were performed in triplicate and experiments were performed 2-3 times.
[0199] Flow cytometry
[0200] Adult mouse sublingual salivary glands (CD1) were dissected and washed in PBS containing gentamicin (Sigma-Aldrich). Cell isolation and flow cytometry were performed as previously described (Muench et al., 2002; Pringle et al., 2011). Briefly, tissues were minced with a scalpel blade in HBSS + 1% BSA (Sigma-Aldrich) and placed in 50 mM CaCl at 37°C. 2(Sigma-Aldrich), 40 mg / ml hyaluronidase (Sigma-Aldrich) and 23 mg / ml type II collagenase (Sigma-Aldrich) in HBSS solution for 15-45 minutes to form a single cell suspension. BSA was added to quench the enzyme reaction, and the solution was filtered through a 70 μm coarse filter (BD Falcon) and centrifuged at 400g for 8 minutes. The resulting cell pellet was washed with sterile HBSS + 1% BSA, centrifuged and resuspended in blocking buffer (5% serum and 0.01% NaN3, BioLegend). The cell suspension was incubated with anti-CD326 antibody (EpCAM; Miltenyi, 130-098-113), rabbit anti-CHRM1 (Research and Diagnostics, AS-3701S), rabbit anti-CHRM3 (Research and Diagnostics, AS-3741S) and rabbit anti-AQP5 (Millipore, AB3559) for cell surface staining. Subsequently, intracellular staining was performed after fixation and permeabilization using an intracellular staining kit (eBioscience, 00-5523-00) and anti-SOX2 (BD Pharmingen, 562195) and Ki67 (BioLegend, 652405) antibodies. Flow cytometry was performed on LSRII (BD) using appropriate single staining controls, and data were collected using FACSDiva (BD) and analyzed using FlowJo. 100,000 events were collected for each sample unless otherwise stated.
[0201] Statistical tests
[0202] Normal distribution was assessed using the D'Agostino-Pearson omnibus test. Data were analyzed for statistical significance using Student's t test (unpaired, two groups) or one-way ANOVA (multiple groups) with post hoc testing using Dunnett or Tukey's test (GraphPad Prism or SPSS). For multiple testing, we used a false discovery rate of 0.05. All graphs show mean + standard deviation (SD) or mean ± standard error of the mean (SEM), as indicated in the figure legends.
[0203] References
[0204] Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C (2006) Detection of the C-KIT (CD117) molecule in benign and malignant salivary gland tumors. Oral Oncology 42: 57-65
[0205] Arnold K, Sarkar A, Yram MA, Polo JM, Bronson R, Sengupta S, Seendel M, Geijsen N, Hochedlinger K (2011) Sox2(+) adult stem and progenitor cells are essential for tissue regeneration and survival in mice. Cell Stem Cell 9: 317-329
[0206] Aure MH, Konieczny SF, Ovitt CE (2015) Maintenance of salivary gland homeostasis by acinar cell self-replication. Developmental Cell 33: 231-237
[0207] Avila JL, Grundmann O, Burd R, Limesand KH (2009) Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis. Int J Rad Oncol Biol Phys 73: 523-529
[0208] Barker N (2014) Adult intestinal stem cells: key drivers of epithelial homeostasis and regeneration. Nature Reviews: Molecular Cell Biology 15: 19-33
[0209] Batt JA, Bain JR (2013) Tibial nerve transection - a standardized model of denervation-induced skeletal muscle atrophy in mice. Journal of Visualized Experiments 81: e50657
[0210] Brady SL, Toncheva G, Dewhirst MW, Yoshizumi TT (2009) A new perspective on characterizing 137Cs irradiators using modern dosimetric tools. Health Physics 97: 195-205
[0211] Brown LR, Dreizen S, Handler S, Johnston DA (1975) Effects of radiation-induced xerostomia on the human oral microbial flora. Journal of Dental Research 54: 740-750
[0212] Coppes RP, Zeilstra LJ, Kampinga HH, Konings AW (2001) Protection against early to late radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists. British Journal of Cancer 85: 1055-1063
[0213] Coppes RP, Vissink A, Konings AW (2002) Comparison of the radiosensitivity of the parotid and submandibular glands in rats after different radiation plans. Radiotherapy and Oncology 63: 321-328
[0214] Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W III, Rudin CM, Dennis PA (2014) SOX2 expression is an early event in a mouse EGFR-mutant lung cancer model and promotes proliferation of a subset of EGFR-mutant lung adenocarcinoma cell lines. Lung Cancer 85: 1-6
[0215] Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic β cells are generated by self-replication rather than stem cell differentiation. Nature 429: 41-46
[0216] Dreizen S, Brown LR, Daly TE, Drane JB (1977) Prevention of xerostomia-related caries in irradiated cancer patients. Journal of Dental Research 56: 99-104
[0217] Dusek M, Simmons J, Buschang PH, al-Hashimi I (1996) Masticatory function in patients with xerostomia. Geriatric Dentistry 13: 3-8
[0218] Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Normal tissue tolerance to therapeutic irradiation. International Journal of Radiation Oncology, Biology, Physics 21: 109-122
[0219] Emmelin N, Holmberg J, Ohlin P (1965) Receptors for catecholamines in the rat submandibular gland. British Journal of Pharmacology and Chemotherapy 25: 134-138
[0220] Emmerson E, May AJ, Nathan S, Cruz-Pacheco N, Lizama CO, Maliskova L, Zovein AC, Shen Y, Muench MO, Knox SM (2017) SOX2 regulates acinar cell development in the salivary gland. eLife 17: e26620
[0221] Erb W(1868)Zur Pathologie und pathologischen Autonomie peripherischer paralysis.Dtsch Arch klin Med 4:535
[0222] Fu SY, Gordon T (1995) Contributing factors to poor functional recovery after delayed nerve repair: chronic denervation. Journal of Neuroscience 15: 3886-3895
[0223] Garrett JR, Ekstrom J, Anderson LC (1999) Neural mechanisms of salivary gland secretion. Basel: Karger
[0224] Giraldo E, Martos F, Gomez A, Garcia A, Vigano MA, Ladinsky H, Sanchez deLa Cuesta F (1988) Characterization of muscarinic receptor subtypes in human tissues. Life Sciences 43: 1507-1515
[0225] Gresz V, Kwon TH, Hurley PT, Varga G, Zelles T, Nielsen S, Case RM, Steward MC (2001) Identification and localization of aquaporin water channels in human salivary glands. Am J Physiol: Gastrointestinal and Hepatic Physiol 281: G247-G254
[0226] Grundmann O, Mitchell GC, Limesand KH (2009) Sensitivity of salivary glands to radiation: from animal models to treatment. Journal of Dental Research 88: 894-903
[0227] Hashimoto S, Chen H, Que J, Brockway BL, Drake JA, Snyder JC, Randell SH, Stripp BR (2012) β-catenin-SOX2 signaling regulates the fate of developing airway epithelial cells. J Cell Sci 125: 932-942
[0228] Hoffman MP, Kidder BL, Steinberg ZL, Lakhani S, Ho S, Kleinman HK, Larsen M (2002) Gene expression profiles of the developing mouse submandibular gland: FGFR1 regulates branching morphogenesis in vitro through BMP- and FGF-dependent mechanisms. Development 129: 5767-5778
[0229] Kang JH, Kim BK, Park BI, Kim HJ, Ko HM, Yang SY, Kim MS, Jung JY, Kim WJ, Oh WM et al. (2010) Parasympathectomy induces morphological changes and alters gene expression profiles in rat submandibular glands. Archives of Oral Biology 55: 7-14
[0230] Klein S, Seidler B, Kettenberger A, Sibaev A, Rohn M, Feil R, Allescher HD, Vanderwinden JM, Hofmann F, Schemann M et al. (2013) Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow wave activity. Nature Communications 4:1630 Klimaschewski L, Grohmann I, Heym C (1996) Target-dependent plasticity of galanin and vasoactive intestinal peptide in the rat superior cervical ganglion after nerve injury and reinnervation. Neuroscience 72:265-272
[0231] Knox SM, Lombaert IM, Reed X, Vitale-Cross L, Gutkind JS, Hoffman MP (2010) Parasympathetic innervation maintains epithelial progenitor cells during salivary gland organogenesis. Science 329: 1645-1647
[0232] Knox SM, Lombaert IM, Haddox CL, Abrams SR, Cotrim A, Wilson AJ, Hoffman MP (2013) Parasympathetic nerve stimulation improves epithelial organ regeneration. Nature: Communications 4: 1494
[0233] Lee NY, Le QT (2008) New advances in radiotherapy for head and neck cancer: intensity-modulated radiotherapy and hypoxia targeting. Oncology Research 35: 236-250
[0234] Lee MJ, Kim EJ, Otsu K, Harada H, Jung HS (2016) Sox2 promotes tooth development via Wnt signaling. Cell Tissue Research 365: 77-84
[0235] Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA, Kok T, Visser WH, Kampinga HH, de Haan G, Coppes RP (2008) Rescue of salivary gland function after transplantation of irradiated glandular stem cells. PLoS One 3:e2063
[0236] Lombaert IM, Abrams SR, Li L, Eswarakumar VP, Sethi AJ, Witt RL, Hoffman MP (2013) Combinatorial KIT and FGFR2b signaling regulates epithelial progenitor expansion during organogenesis. Stem Cell Reports 1:604-619 van Luijk P, Pringle S, Deasy JO, Moiseenko VV, Faber H, Hovan A, Baanstra M, van der Laan HP, Kierkels RG, van der Schaaf A et al. (2015) Preservation of salivary gland regions containing stem cells for sustained saliva production after radiotherapy for head and neck cancer. Science Translational Medicine 7:305ra147
[0237] Lujan M, Paez A, Llanes L, Angulo J, Berenguer A (1998) Role of autonomic innervation in the maintenance of prostate architecture in the rat: a morphometric analysis. Journal of Urology 160: 1919-1923
[0238] Mandour MA, Helmi AM, El-Sheikh MM, El-Garem F, El-Ghazzawi E (1977) Effects of tympanic neurectomy on the human parotid salivary glands. Histopathological, histochemical and clinical studies. Archives of Otolaryngology 103: 338-341
[0239] Marmary Y, Adar R, Gaska S, Wygoda A, Maly A, Cohen J, Eliashar R, Mizrachi L, Orfaig-Geva C, Baum BJ et al. (2016) Radiation-induced loss of salivary gland function is driven by cellular senescence and suppressed by IL6 regulation. Cancer Research 76: 1170-1180
[0240] Mei L, Roeske WR, Izutsu KT, Yamamura HI (1990) Characterization of muscarinic acetylcholine receptors in human labial salivary glands. European Journal of Pharmacology 176: 367-370
[0241] Muench MO, Suskind DL, Barcena A (2002) Isolation, growth and characterization of colony-forming cells with erythroid, myeloid, dendritic and NK cell potential from human fetal liver. Bioprocedure Online 4: 10-23
[0242] Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L (2007) Whole-body dual fluorescent Cre reporter mouse. Genesis 45:593-605
[0243] Nakamura E, Nguyen MT, Mackem S (2006) Using cartilage-specific CreER(T) to characterize the kinetics of tamoxifen-regulated Cre activity in mice to determine temporal windows of activity along the proximal and distal limb skeleton. Developmental Dynamics 235: 2603-2612
[0244] Nanduri LS, Lombaert IM, van der Zwaag M, Faber H, Brunsting JF, van OsRP, Coppes RP (2013) Salisphere-derived c-Kit cell transplantation restores tissue homeostasis in irradiated salivary glands. Radiol Oncol 108: 458-463
[0245] Nanduri LS, Baanstra M, Faber H, Rocchi C, Zwart E, de Haan G, van Os R, Coppes RP (2014) Purification and in vitro expansion of fully functional salivary gland stem cells. Stem Cell Reports 3: 957-964
[0246] Nelson DA, Manhardt C, Kamath V, Sui Y, Santamaria-Pang A, Can A, Bello M, Corwin A, Dinn SR, Lazare M et al. (2013) Quantitative single-cell analysis of cell population dynamics during development and differentiation of the submandibular salivary gland. Open Biology 2: 439-447
[0247] Ogawa M, Oshima M, Imamura A, Sekine Y, Ishida K, Yamashita K, Nakajima K, Hirayama M, Tachikawa T, Tsuji T (2013) Functional salivary gland regeneration by bioengineered organoid embryo transplantation. Nature: Communications 4: 2498
[0248] Owens DM, Watt FM (2003) Contribution of stem cells and differentiated cells to epidermal tumors. Nature Reviews Cancer 3: 444-451
[0249] Patterson J, Lloyd LC, Titchen DA (1975) Secretory and structural changes in the parotid salivary glands of sheep and lambs following parasympathetic denervation. Quarterly Journal of Experimental Physiology and Allied Medical Sciences 60: 223-232
[0250] Peng X, Varendi K, Maimets M, Andressoo JO, Coppes RP (2017) Role of glial cell-derived neurotrophic factor in the response of salivary gland stem cells to radiation. Radiotherapy and Oncology 124: 448-454
[0251] Peterson SC, Eberl M, Vagnozzi AN, Belkadi A, Veniaminova NA, Verhaegen ME, Bichakjian CK, Ward NL, Dlugosz AA, Wong SY (2015) Basal cell carcinomas preferentially originate from stem cells in the hair follicle and mechanosensory niche. Cell Stem Cell 16: 400-412
[0252] Pringle S, Nanduri LS, van der Zwaag M, van Os R, Coppes RP (2011) Isolation of mouse salivary gland stem cells. Journal of Visualized Experiments 8: 2484
[0253] Pringle S, Maimets M, van der Zwaag M, Stokman MA, van Gosliga D, Zwart E, Witjes MJ, de Haan G, van Os R, Coppes RP (2016) Human salivary gland stem cells restore salivary gland function after radiation damage. Stem Cells 34: 640-652
[0254] Que J, Luo X, Schwartz RJ, Hogan BL (2009) Multiple roles of Sox2 in the developing and adult mouse trachea. Development 136: 1899-1907
[0255] Raz E, Saba L, Hagiwara M, Hygino de Cruz LC Jr, Som PM, Fatterpekar GM (2013) Parotid gland atrophy in patients with chronic trigeminal denervation. AJNR American Journal of Neuroradiology 34: 860-863
[0256] Redman RS (2008) Methods for restoring salivary gland function after radiotherapy for head and neck cancer and a review of related aspects of salivary gland morphology and development. Biotechnology and Histochemistry 83: 103-130
[0257] Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S et al. (2015) Inhibition of mutant EGFR triggers a SOX2-FOXO6-dependent survival pathway in lung cancer cells. eLife 4:e06132
[0258] Schneyer CA, Hall HD (1967) Effects of denervation on the functional and structural development of the parotid gland in the immature rat. Am J Physiol 212: 871-876
[0259] Seidel K, Marangoni P, Tang C, Houshmand B, Du W, Maas RL, Murray S, Oldham MC, Klein OD (2017) Dissecting stem and progenitor cells in the adult mouse incisor by gene co-expression analysis. eLife 5: e24712
[0260] Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Clinic Cancer 65: 5-29
[0261] Smith AN, Miller LA, Radice G, Ashery-Padan R, Lang RA (2009) Stage-dependent patterning of Pax6-Sox2 ectopy regulates lens development and eye morphogenesis. Development 136: 2977-2985
[0262] Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF (2005) Chemoradiotherapy-induced cell loss in the human submandibular gland. Laryngoscope 115:958-964
[0263] Suzuki Y (2008) Sox2 expression in mouse taste buds and its relationship to neural innervation. Cell Tissue Research 332: 393-401
[0264] Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH (2006) SOX2 is a dose-dependent regulator of retinal neural progenitor cell competence. Genes & Development 20: 1187-1202
[0265] Tatsuta M, Yamamura H, Iishi H, Ichii M, Noguchi S, Baba M, Taniguchi H (1985) Promotion of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats by vagotomy. Cancer Res 45: 194-197
[0266] Tofilon PJ, Fike JR (2000) Radiation response of the central nervous system: a dynamic process. Radiation Research 153: 357-370
[0267] Ueno H, Ferrari G, Hattori T, Saban DR, Katikireddy KR, Chauhan SK, Dana R (2012) Dependence of corneal stem / progenitor cells for ocular surface innervation. Ophthalmic Research and Vision 53: 867-872
[0268] Urek MM, Bralic M, Tomac J, Borcic J, Uhac I, Glazar I, Antonic R, Ferreri S (2005) Early and late effects of X-radiation on the submandibular gland: a morphological study in mice. Archives of Medical Research 36: 339-343
[0269] Von Vintschgau M,Honigschmied J(1877)Nervus GlossopharyngeusundSchmeckbecher.Arch Gesammte Physiol 14:443-448
[0270] Wallace H (1972) Regenerative neural components supporting limb regeneration in irradiated salamanders. Journal of Embryology and Experimental Morphology 28: 419-435
[0271] Wang JM, McKenna KE, McVary KT, Lee C (1991) Neural requirements for maintaining the structural and functional integrity of the rat prostate. Biology of Reproduction 44: 1171-1176
[0272] Wanigasekara Y, Airaksinen MS, Heuckeroth RO, Milbrandt J, Keast JR (2004) Neurotrophin signaling through GFRalpha2 is essential for the innervation of glandular but not muscle targets by sacral parasympathetic ganglion neurons. Cellular and Molecular Neuroscience 25: 288-300
[0273] Wollny D, Zhao S, Everlien I, Lun X, Brunken J, Brune D, Ziebell F, Tabansky I, Weichert W, Marciniak-Czochra A et al. (2016) Single-cell analysis reveals clonal acinar cell heterogeneity in the adult pancreas. Developmental Cell 39: 289-301
[0274] Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Molecular Interventions 4: 273-284
[0275] Wu S, Wu Y, Capecchi MR (2006) Motor neurons and oligodendrocytes arise sequentially from neural stem cells but do not appear to share common lineage-restricted progenitors in vivo. Development 133: 581-590
[0276] Xiao N, Lin Y, Cao H, Sirjani D, Giaccia AJ, Koong AC, Kong CS, Diehn M, LeQT (2014) The neurotrophic factor GDNF improves the survival of salivary gland stem cells. Journal of Clinical Invest 124: 3364-3377
[0277] Xiao Y, Thoresen DT, Williams JS, Wang C, Perna J, Petrova R, Brownell I (2015) Neural hedgehog signaling maintains stem cell renewal in the sensory touch dome epithelium. Proceedings of the National Academy of Sciences of the United States of America 112: 7195-7200
[0278] Yawo H (1987) Changes in dendritic geometry of superior cervical ganglion cells in mice after postganglionic axonal microsurgery. Journal of Neuroscience 7: 3703-3711
[0279] Zeilstra LJ, Vissink A, Konings AW, Coppes RP (2000) Radiation-induced cell loss in the rat submandibular gland and its relationship to glandular function. Int J RadBiol 76: 419-429
[0280] Zhao CM, Hayakawa Y, Kodama Y, Muthupalani S, Westphalen CB, Andersen GT, Flatberg A, Johannessen H, Friedman RA, Renz BW et al. (2014) Denervation inhibits gastric tumorigenesis. Science Translational Medicine 6: 250ra115
[0281] Example 2
[0282] Therapeutic activation of endogenous saliva by local delivery of muscarinic agonists in injectable alginate hydrogels Fluid gland stem cell population
[0283] Another regenerative approach to restore salivary gland function is stem cell therapy, i.e., transplantation of autologous stem / progenitor cells into damaged organs or reactivation of surviving stem cells within tissues. However, it was not previously known that progenitor cells that give rise to salivary acinar cells are the primary cell type damaged by radiation and autoimmune disease. We recently identified SOX2 as a marker for epithelial progenitor cells in murine salivary glands (Emmerson et al., 2018). SOX2+ acinar cells are present in all major human salivary glands, the submandibular gland (SMG), and constitute 20% of the acinar compartment in the murine sublingual gland (SLG). We found that maintenance of SOX2+ cell and tissue homeostasis depends on parasympathetic nerve production of acetylcholine, which activates muscarinic receptors to promote cell proliferation. We further demonstrated that the muscarinic mimetics carbachol and pilocarpine promoted SOX2+ cell proliferation after in vivo and / or ex vivo delivery, and that muscarinic agonism promoted salivary gland regeneration after radiation-induced injury. Together, these studies strongly suggest that reactivating existing stem cells is a viable strategy for regenerating organs.
[0284] In this study, we tested the ability of local and sustained delivery of cevimeline to promote stem cell-mediated salivary gland repopulation. Specifically, we designed a combination product involving the encapsulation of a muscarinic agonist in a biodegradable cross-linked calcium alginate hydrogel for local, targeted, and sustained delivery into the salivary glands. Combining in vitro and in vivo testing, we identified the chemistry of an alginate-based hydrogel that enables linear distribution within tissues and sustained delivery of the muscarinic receptor agonist cevimeline. In vivo testing in mice demonstrated that the encapsulated drug effectively promoted stem cell proliferation within the salivary glands of both control and irradiated animals in a manner consistent with sustained delivery. Thus, we provide a novel therapeutic approach for salivary gland regeneration and restoration of salivary flow.
[0285] result
[0286] Cevimeline promotes cell proliferation when administered via local injection
[0287] Given our previous findings that systemic administration of muscarinic mimetics promotes salivary gland proliferation, we next determined whether local intraglandular injection could also promote a mitogenic response. To determine whether Cevimeline could act locally in the salivary glands to induce acinar cell proliferation, we injected Cevimeline directly into the sublingual glands at a dose of 10 mg / kg body weight (20 μL) and measured proliferation 18 hours later. As shown in Figure 15, acinar cell proliferation was significantly increased (Figure 15), indicating that Cevimeline can act directly in the salivary glands to promote cell mitosis.
[0288] Engineering biodegradable cross-linked calcium alginate hydrogel
[0289] Based on the efficacy of local delivery of Cevimeline in promoting cell proliferation, we next set out to develop an injectable drug delivery platform to locally release and sustain Cevimeline to drive acinar regeneration. To this end, we chose to use a cross-linked calcium alginate-based biomaterial to deliver Cevimeline. Alginate is a naturally occurring anionic polymer extracted from brown algae. Alginate is an FDA-approved hydrogel for many biomedical applications. It is biocompatible, minimally toxic, relatively low cost, and has the advantages of being cytocompatible with divalent cations such as Ca. 2+ ) ability to undergo cross-linking. (Lee et al. (2012) Adv. in Polym. Sci. 37(1):106-126) Cross-linked calcium alginate has a similar structure to the extracellular matrix of living tissues and is highly hydrophilic, maintaining a physiologically moist microenvironment. Importantly for our application, alginate can be resuspended at a concentration that allows injection via a clinically relevant syringe-needle system, during which shear forces disrupt the electrostatic cross-links, causing the material to deform linearly, but the gel will spontaneously reform in vivo.
[0290] Alginate is intrinsically non-degradable in mammals due to the lack of the polymer chain cleaving enzyme alginate. However, ionically cross-linked alginate gels dissolve by releasing divalent ions, which cross-link the gel to the surrounding medium through exchange reactions with monovalent cations (e.g., sodium ions). The alginate degradation rate can be further controlled by partial oxidation of the polymer chains. Alginate hydrogels must degrade within 30 days after injection, which is critical for FDA approval as a therapeutic agent rather than an implantable. However, to achieve sustained delivery of cevimeline, the presence of alginate should exceed 7 days. To meet this degradation characteristic, we partially oxidized 2% or 5% of the alginate chains. In vitro degradation tests showed that the two hydrogels had significantly different degradation profiles, with the 2% oxidized alginate (OA) hydrogel degrading more slowly. ( Fig.16A ) 2% OA hydrogels can maintain more than 50% of their gel mass for nearly 5 days in vitro, while 5% OA hydrogels cannot maintain this mass after 1 day. In the in vitro degradation test, about 30% of 2% OA hydrogels and 14% of 5% OA hydrogels were retained after 7 days of culture.
[0291] Based on this longer physical retention time, we chose to continue using 2% OA hydrogels. We next tested how the weight percentage (wt%) of the 2% OA hydrogel affected physical degradation. Although 10wt% of the 2% OA hydrogel degraded significantly slower than either the 2wt% or 5wt% hydrogels, this concentration cannot be easily injected through the small-caliber needles (>23 gauge) required for in vivo delivery to the salivary glands. ( Fig. 16B )
[0292] The physical degradation of 2% OA hydrogel (5 wt%) was then tested under more physiologically relevant conditions by injecting 100 μL of hydrogel into a subcutaneous pocket on the dorsal flank of wild-type mice. This amount of hydrogel formed a small disk within a few minutes, which could then be removed and weighed for analysis. In contrast to the in vitro system, we found that there was little mass loss after 7 days of in vivo injection ( Fig. 16C ), indicating that the hydrogel is suitable for the in vivo delivery of cevimeline.
[0293] Another factor that is critical to commercial potential is the storage stability of the dissolved alginate. To slow degradation, we assume that the dissolved oxidized alginate material must be stored at 4°C or <-20°C, but it is currently unclear how these storage conditions specifically affect the stability of the material. Therefore, we tested the changes in the compression modulus of the cross-linked calcium alginate after the dissolved oxidized alginate was stored at 4°C or -20°C for 30 days. When the 2% OA hydrogel (5wt%) was stored under refrigerated conditions (4°C), the cross-linking efficacy was significantly affected, and the compression modulus showed a decrease at 20 days of storage, indicating that the oxidized alginate was degraded ( Fig. 16C ). However, when the alginate was stored under frozen conditions (-20°C), the initial material properties of the alginate remained stable 30 days after synthesis.
[0294] Topical and sustained release of cevimeline from alginate hydrogels
[0295] The pharmaceutical application of alginate has traditionally involved the controlled release of a variety of low molecular weight drugs using hydrogels. Cross-linked alginate can form nanoporous materials. The theoretical pore size of the material we used was about 5nm and the starting molecular weight was 197kDa. The controlled drug release was mainly regulated by the electrostatic interaction between the positively charged cevimeline (pKA = 9.5) and the negatively charged alginate hydrogel. In vitro cevimeline release studies showed that we could release the drug over a period of 2 days. (Figure 17) Although the physical degradation properties were changed ( Figures 16A-16B ), but the oxidation amount (OA%) and weight percentage (wt%) of alginate hydrogels had no significant effect on the drug release kinetics, and more than 85±5% of cevimeline was released in vitro within 2 days. ( Figures 17A-17B ) To test whether changing the starting concentration of the drug affects release, we loaded 3,000, 60,000, or 12,000 ng of cevimeline into each disk and tested the in vitro release. The release rate remained relatively consistent ( Fig. 17C ), thus, drug delivery increased predictably over a two-day period ( Fig.17D ).
[0296] Cevimeline promotes glandular cell proliferation when encapsulated in alginate
[0297] Given this successful drug delivery platform, we next tested the in vivo efficacy, toxicity, and degradation of alginate + cevimeline. Due to the small size of mouse salivary glands, we chose not to inject the hydrogel directly into the glands to avoid complications caused by tissue damage, but instead injected the hydrogel into an area directly adjacent to the glands that could be observed by X-ray ( Fig.18A; Omnipaque encapsulated as a radiopaque contrast agent). Alginate or saline with or without 10 mg / kg cevimeline was injected into the area adjacent to the salivary glands and the salivary glands were resected 18 h after injection ( Fig. 18C Salivary glands were analyzed at 10 mg / kg alginate + cevimeline (n=3-4 / group) or 3 days (Figure 18, n=3-6 / group). As shown in Figure 18, we measured a significant increase in the number of Ki67+ and EdU+ acinar cell proliferation in response to 10 mg / kg alginate + cevimeline on day 3 compared to alginate alone ( Fig. 18C ), which is consistent with the prolonged activity of the drug when used in combination with alginate. We observed a similar increase in the number of Ki67+ acinar cells proliferating in response to the higher 25mg / kg alginate + cevimeline at day 3, indicating that increasing the dose did not significantly improve efficacy (Figure 18). We also tested whether alginate itself was mitogenic by comparing cell proliferation in the glands of mice treated with alginate alone with that of mice that received intraperitoneal (IP) injections of saline alone. We found that alginate alone was sufficient to promote epithelial cell proliferation and that this effect was maintained over a period of 3-7 days ( Fig.23 ), indicating that the combination has a beneficial effect.
[0298] To determine whether alginate or alginate + cevimeline treatment produced toxic effects in mice, we measured body weight and characterized inflammatory cells in their salivary glands. We found that increasing doses of alginate + cevimeline did not result in weight loss by day 3 post-injection ( Fig.24 In addition, no toxic effects such as diarrhea were observed compared with the saline-injected control group. Our immunohistological analysis of CD3+ T cells also showed no increase ( Fig.19A , 19B Our analysis of CD68+ macrophages, a key innate immune cell and first responder to injury, showed a slight increase in these cells in response to alginate or alginate + cevimeline administration compared directly to untreated controls ( Fig.19C , 19D Further analysis of the macrophage population showed a significant increase in pro-repair CD206+ macrophages in tissues that received alginate compared to controls that received saline ( Fig.19E ), suggesting that alginate may have beneficial effects on salivary glands by activating anti-inflammatory macrophages.
[0299] Effects of Cevimeline-Alginate on Salivary Glands after Radiation-Induced Injury
[0300] Next, we tested whether cevimeline or alginate + cevimeline could promote cell proliferation in the salivary glands after gamma-irradiation-induced injury. 7-8 week old C57BL6 mice were irradiated with a single 10 Gy dose to the neck and injected systemically or intragastrically with saline or 10 mg / kg cevimeline 14 days later. The number of proliferating acinar cells was analyzed 18 hours later (see Fig. 20A This level of radiation reduced citrate-induced salivary flow by 30% ( Fig. 20B We found that both systemic and local administration of cevimeline increased the proliferation of acinar cells in irradiated mice ( Figures 20C-20E ), which suggests that cevimeline is effective for damaged salivary glands.
[0301] Finally, we tested whether cevimeline encapsulated in alginate could promote cell proliferation and salivary flow. Mice were injected with alginate or alginate + cevimeline 14 days after RT and sacrificed on day 3 for proliferation analysis ( Fig.21A Schematic diagram). Alginate + Cevimeline resulted in a proliferation rate higher than the proliferation rate obtained with alginate alone ( Fig.21B , 21C We further determined whether treatment with alginate or alginate + cevimeline could improve salivary flow. Surprisingly, both alginate and alginate + cevimeline enhanced the citrate-induced increase in salivary flow, and the effect persisted for 7 days ( Fig.21D ), suggesting that alginate itself is beneficial to irradiated organs.
[0302] discuss
[0303] Oral muscarinic agonists stimulate temporary saliva production in patients with xerostomia but are associated with common side effects such as hyperhidrosis, flushing, urinary urgency, gastrointestinal upset, and headache. In this study, we demonstrate that local release of the muscarinic agonist cevimeline from an injectable cross-linked calcium alginate hydrogel promotes recruitment of acinar cells and improves salivary gland function after radiation-induced injury without eliciting an immune response. This represents the first in vivo evidence that acinar progenitor cells in irradiated tissue can be stimulated to proliferate and that muscarinic receptor activation is sufficient to achieve this outcome. We also demonstrate that the use of cross-linked calcium alginate alone, in addition to sustained release of small-molecule cevimeline over three days, stimulates a pro-regenerative response. Taken together, these findings provide a potential new combination therapy for reversing salivary gland dysfunction after radiation-induced injury, which could be applicable to a range of xerostomia conditions.
[0304] Our therapeutic approach is based on evidence from the past 100 years that peripheral nerves are essential for salivary gland function, homeostasis, and regeneration. Parasympathetic nerve ablation results in atrophy of the secretory alveoli, which can be reversed by reinnervation of the tissue (Emmerson et al., 2018). Since parasympathetic innervation is severely reduced in salivary glands of patients undergoing therapeutic radiation for head and neck cancer (Emmerson et al., 2018), we questioned whether resupplying atrophic tissue with neurogenic factors could restore tissue structure and function. The in vivo experiments presented here follow up on our previous in vitro studies, which showed that increased neuronal survival and improved function in fetal salivary glands following radiation exposure or treatment of irradiated adult tissue with muscarinic agonists was sufficient to promote recruitment of acinar cells through a progenitor cell-mediated mechanism (Knox, 2013; Emmerson, 2018). Furthermore, our current data also suggest that the improvement in salivary flow in mice and humans with irradiated salivary glands following chronic oral administration of muscarinic agonists (Barbe 2017; Taniguchi 2019) may be due to acinar cell recruitment rather than reduced cell death. However, whether human acinar cells can proliferate in response to muscarinic stimulation remains to be determined.
[0305] Many strategies have been explored for regeneration of irradiated salivary glands. Our therapeutic application aims to mimic the endogenous regulation of the tissue by the parasympathetic nervous system by providing an acetylcholine homologue. This approach is consistent with recent gene therapy studies that aim to resupply the organ with functional nerves through the expression of neurotrophin, a neurotrophic growth factor. Other strategies utilize growth factors known to promote branching morphogenesis during embryonic development: intraglandular administration of fibroblast growth factor 7 (FGF7; Lombaert et al., 2009; Xiao et al., 2014), or systemic administration of insulin-like growth factor 1 (Grundmann (2010) BMC Cancer 10:417) or genetic delivery of sonic hedgehog (Shh) by catheterization (Hai et al. (2016) Human Gene Therapy. 27(5):390-399) to irradiated salivary glands improves salivary function and tissue preservation. However, clinical uptake of these factors has been hampered by their potential to accelerate cancer cell growth. Although long-term oral administration of pilocarpine did not demonstrate tumorigenicity, further studies are needed to determine whether topical administration of cevimeline affects cancer initiation, progression, or metastasis.
[0306] Previous studies have shown that cross-linked calcium alginate hydrogels can promote wound healing in various organ systems including bone, cartilage, and skin (Wang et al. (2015) Int J Clin Exp Pathol. 8(6):6636-6645). However, whether this function is mediated directly through cell proliferation, survival, and / or migration remains poorly understood. Our data suggest that calcium alginate is able to promote tissue regeneration in irradiated salivary glands by inducing cell proliferation. A potential mechanism for achieving this is increased extracellular calcium. Calcium that is not cross-linked to the polysaccharide backbone is either released directly from alginate into the extracellular space (Doyle et al. (1996) J Biomed Mater Res. 32(4):561-568) or can be released during material degradation. This Ca is then released into the extracellular space. 2+ Depots can activate calcium sensing receptors to mediate intracellular Ca 2+ Since calcium sensing receptors are present on many cell types, including acinar cells, we propose that Ca from alginate 2+ Ions can act as mitogens by stimulating these receptors.
[0307] Recently, it has been reported that Ca in alginate gel 2+ The release of cevimeline may also be pro-inflammatory (Chan et al. (2013) Acta Biomaterialia Sinica. 9(12):9281-9291). Subcutaneous injection of calcium alginate into mice significantly upregulated IL-ip in surrounding tissues and enhanced the inflammatory effects of LPS. However, our results showed that calcium alginate, with or without cevimeline, was highly biocompatible and caused little inflammation when injected into the immediate vicinity of the salivary glands.
[0308] One of the key properties that hydrogels need to provide is the ability to release drugs in a controlled manner. Drug molecules, ranging from smaller chemical drugs to larger proteins, can be released from alginate gels in a controlled manner, depending on the type of crosslinker and the crosslinking method. In fact, a variety of chemistries have been applied to control the kinetics of drug release, such as crosslinking.
[0309] Materials and methods
[0310] Synthetic OA
[0311] Oxidized alginate (OA) was prepared by reacting sodium alginate (Protanal LF 20 / 40, alginate MW = 197,000 Da, FMC Biopolymer Catalog No. S18407) with sodium periodate (Sigma, Catalog No. 311448) by modifying a previously described method. [1] In brief, sodium alginate (10 g) was dissolved in ultrapure deionized water (diHO).2 Sodium periodate (0.22 g) was dissolved in 100 ml diH 2 O, and then added to the alginate solution at room temperature (RT) and stirred in the dark. After 24 h of reaction, ethylene glycol (52 μL, Sigma) was added to terminate the reaction. 2 OA was purified by dialysis (MWCO=3500Da, Spectrum Laboratories Inc.) for 3 days, then treated with activated carbon (5 g / l, 50-200 mesh, Fisher, 05-690B) for 30 minutes, filtered (0.22 μm filter) and lyophilized.
[0312] To analyze the oxidation efficiency of OA, OA was dissolved in deuterium oxide (5 w / v%) and placed in an NMR tube. 4 The sodium salt (0.05 w / v%) was used as an internal standard and recorded on a Bruker ADVANCE III 400 MHz NMR spectrometer (Bruker). 13 C-NMR spectrum. Based on the integrated ratio of carbon to the carbonyl carbon of the newly formed aldehyde by oxidation of alginate, 13 The actual oxidation conditions were confirmed by H-NMR spectroscopy. Fig.25 ).
[0313] Synthesis of calcium-crosslinked OA hydrogels
[0314] OA was stored in lyophilized form at -20°C until ready to be made into hydrogels. The hydrogels were prepared as follows: OA was dissolved in Dulbecco's Modified Eagle Medium (DMEM, Gibco Cat. No. 11885084) and stirred continuously at room temperature for at least 30 minutes until the desired weight / volume ratio (wt%) was reached. OA was mixed with supersaturated calcium sulfate (CaSO 4 , 84 mg / mL) solution with a concentration of 20 μL CaSO 4 / 1wt% / mL alginate (e.g. 40, 100 and 200 μL CaSO 4 OA solution and CaSO 4 The slurry was loaded into two 1 mL syringes, respectively. After the two syringes were connected together using a female-female Luer lock connector (Value Plastics), the two syringes were mixed (about 30 times).
[0315] Physical degradation of oxidized alginate hydrogels
[0316] The in vitro physical degradation of OA hydrogels was tested by forming 1 mm × 4 mm disks with an oxidation rate of 2% or 5% and a weight / volume ratio of 2, 5, or 10 wt%. The disks were formed by injecting the OA hydrogel between two glass plates separated by a 1.0 mm spacer using a 25-gauge needle. After the gel was polymerized at room temperature for 30-45 minutes, it was made into a disk with a diameter of 4 mm using a biopsy punch. The gel was transferred to a 0.4 μm transwell chamber (Millicell, Cat. No.: MCHT12H48) in a 12-well plate containing 3.2 ml of DMEM and the plate was continuously shaken (100 RPM) at 37°C. The plate was incubated at T 0 (initial control), 4 hours, 1 day, 3 days, 5 days and 7 days (D) were collected. The three hydrogels were pooled together, and there were 3-5 independent replicates (samples) at each time point on average. The samples were frozen at -80°C and then freeze-dried (VirTisWizard 2.0). The dry weight was measured using an analytical balance (Mettler Toledo AT201).
[0317] In vivo degradation assays were performed by subcutaneous assays in mice. All experiments have been approved by the UCSF Institutional Animal Care and Use Committee (IACUC). Animals were anesthetized with isoflurane (2.5% induction, 1.5% maintenance), the animal skin was cleaned with 70% ethanol, and then 100 μL of OA hydrogel was injected into each subcutaneous pocket on the back of the mouse using a 25-gauge needle (up to 6 hydrogels / animal). Mice were group-housed and monitored for 48 hours for signs of pain and distress. The animals survived for 18 hours, 3 days, 5 days, or 7 days. At the terminal time point, the gel in the subcutaneous pocket was microdissected, frozen at -80°C, lyophilized, and the dry weight was recorded, as shown in the in vitro degradation assay.
[0318] OA stability
[0319] As described above, 2% OA polymer was dissolved at 5 wt%, then drawn into a 3 ml syringe and stored at 4°C or -20°C. The stored syringes (n=5 / times) were taken out 1, 4, 10, 20 or 30 days after dissolution, allowed to reach room temperature, and then crosslinked by mixing the OA solution with the above-mentioned supersaturated calcium sulfate slurry. After mixing, the crosslinked OA was immediately placed between two glass plates separated by a 0.75 mm spacer and allowed to stand at room temperature for 30 minutes to form a hydrogel. Calcium-crosslinked OA hydrogel discs were made using a biopsy punch with a diameter of 6 mm. In order to evaluate the stability of the OA solution, the modulus of the calcium-crosslinked OA hydrogel over time was measured. The elastic modulus of the hydrogel was determined as follows: at room temperature, at a constant crosshead speed of 1%, a uniaxial, unrestricted constant strain rate compression test was performed on a mechanical testing machine (225 lbs Actuator, Test Resources) equipped with a 5N load cell. The elastic modulus is calculated from the first non-zero linear slope of the stress-strain diagram and is limited to the value corresponding to the first 5% strain.
[0320] Measurement of Cevimeline by Mass Spectrometry
[0321] LC-MS / MS analysis was performed using a Shimadzu Prominence LC-20ADXR system interfaced to a 4500QTrap mass spectrometer with an electrospray ionization (ESI) source. Chromatographic separation was achieved using a C18 (50×3 mm, 2.6 μm) column and a Phenomenex SecurityGuard C18 guard column (3 mm×2.0 mm). The column temperature was controlled at 30 °C. Mobile phase A was 0.1% trifluoroacetic acid in water, and mobile phase B was acetonitrile (ACN). The injection volume was 10 μL, and the flow rate was 0.5 mL / min. The gradient conditions were (time / min, % mobile phase B): (0,15), (1,15), (2.5,22.8), (2.6,98), (5,98), (5.1,15), and (8,15). The source parameters included a curtain gas pressure of 45 psi, an ion spray voltage of 4000 V, an ion source temperature of 550, and a medium collision gas. The MS / MS parameter settings in the positive ion ESI mode are summarized in Table 1.
[0322] Prepare Cevimeline standard working solutions in methanol at concentrations ranging from 10.0-10000.0 ng / mL. Add the working solutions to 100 μL of DMEM to generate standards or QC samples. The final concentrations of calibration standards in DMEM are 0.5, 1.0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100.0, 250.0 and 500 ng / mL. The QC sample concentrations are 0.9, 4, 30.0 and 400.0 ng / mL.
[0323] For the sample preparation step, 10 μL of IS working solution (1000 ng / mL) was added to each 100 μL of DMEM. Protein precipitation was performed using a 96-well protein precipitation filter plate (Sigma-Aldrich (St. Louis, MO)) and 300 μL of MeOH:ACN (15:85). After filtration, 200 μL of NH 4 OH 5% was added to 200 μl of sample and 10 μl was injected into the LCMS system. The bioanalytical method was validated according to current US FDA guidance, including selectivity, linearity, intra- and inter-day precision and accuracy, recovery, and stability (“Guidance for Industry, Validation of Bioanalytical Methods”, 2018fda.gov / media / 70858 / download).
[0324] Table 1. Optimized ESI(+) mass spectrometry conditions for multiple reaction monitoring (MRM) of the compounds.
[0325]
[0326] Release of Cevimeline from Alginate Hydrogels
[0327] In vitro cevimeline (CV) release from OA hydrogels was tested by forming 1 mm × 4 mm disks with 2% or 5% oxidation and 2, 5, or 10% weight / volume ratios. Alginate + cevimeline (Abcam, ab141317) hydrogels were prepared as follows: the drug was resuspended in DMEM at the desired concentration before mixing with lyophilized OA, followed by cross-linking as described above to encapsulate the drug with the OA hydrogel. Three 4 mm alginate + cevimeline hydrogels were placed in 0.4 μm transwell chambers in 12-well plates containing 3.2 ml DMEM and incubated at 37°C with slow continuous stirring (100 RPM). Sample culture medium (3 ml DMEM) was collected and supplemented at 4 hours, 1 day, 2 days, 3 days, 4 days, 5 days, and 7 days (D). The three hydrogels were pooled together, and 3-5 independent replicates (samples) were averaged for each time point. Sample culture media were stored at -20°C until mass spectrometry analysis. The graph shows only relevant data up to day 4, as all cevimeline had been released by then. 0 (Initial Control) Gels were dissolved in DMEM to determine the baseline of Cevimeline encapsulated in the hydrogels.
[0328] Animal experiments
[0329] Unless otherwise stated, all experiments used adult female mice (6-8 weeks old) from the C57 / BL6 inbred strain (Harlan Laboratories). All procedures were approved by the UCSF Institutional Animal Care and Use Committee (IACUC) and adhered to the NIH Guide for the Care and Use of Laboratory Animals.
[0330] In vivo Cevimeline delivery
[0331] Cevimeline was prepared as described above and then 0.5 ml Monojec tTM Free cevimeline was delivered by intraperitoneal (IP) injection using a tuberculin syringe and a 28G 1 / 2 needle (Covidien), or the alginate and cevimeline mixture was delivered by subcutaneous injection using a 1 ml TB syringe and a 25G x 5 / 8 needle (Becton Dickinson).
[0332] For intraglandular injection of cevimeline, mice were given analgesics (carprofen and buprenorphine; Patterson Veterinary and Buprenex; 0.1 mg / kg and 100 mg / kg (IP), respectively) 30 min before surgery and maintained in the ventricular cavity by inhalation of 2% isoflurane / O 2Mixture anesthesia. Shave the surgical area and prepare an incision, clean it with iodine and alcohol alternately, and then apply local anesthetic (lidocaine; Hospira Inc., 8mg / kg). Use spring scissors to cut an incision in the throat along the head and tail axis. Then use 2 27Gx1 / 2 needles (Becton Dickinson) installed on a sliding tip tuberculin syringe (Becton Dickinson) to inject Cevimeline into the lobes of the submandibular and sublingual salivary glands. Use non-absorbable suture silk (Ethicon) to suture the skin. At the 18th hour, the 3rd day or the 7th day, mice were euthanized, and some animals were injected with 0.9% saline containing 0.25mg / 25g 5-ethynyl-2'-deoxyuridine (EdU, ThermofisherScientific) 2 hours before being killed.
[0333] -Radiation therapy
[0334] Animals were anesthetized with 100 μl / 10 g bw 2.5% avertin (2,2,2-tribromoethanol (Alfa Aesar), tert-amyl alcohol (2-methyl-2-butanol) (Spectrum)) in 0.9% saline (Vedco Inc.). Mice were placed in a Shepherd Mark I irradiator (JL Shepherd & Associates). The body was shielded from radiation using lead blocks, and the head and neck area were exposed to 2 doses of 5 Gy (10 Gy total) to irradiate the salivary glands (SG). Control mice were anesthetized but not irradiated. All mice were allowed to fully recover before being returned to normal housing and given a soft diet ad libitum (ClearH 2 O).
[0335] Saliva collection
[0336] Mice were anesthetized using 2% inhaled isoflurane or avertin (for radiation studies). 5 mg of sodium citrate (Spectrum Chemical) dissolved in 12.5 μl of sterile water was dripped into the mouth of the mouse. After 2 minutes, a piece of filter paper was inserted into the mouth of the animal and left for 5 minutes while the animal was anesthetized. The amount of saliva secretion was determined by measuring the weight of the filter paper before and after collection using a precision scale (Denver Instrument SI-64, di=0.1 mg).
[0337] Tissue processing
[0338] After euthanasia, SGs were collected, snap frozen and embedded in OCT. 10 μm cryosections were cut using a cryostat (Leica) and used for immunofluorescence studies.
[0339] Immunofluorescence studies
[0340] Tissue section immunofluorescence analysis is carried out as follows.In brief, fresh frozen tissue was fixed with 4% PFA for 10 minutes at room temperature, then permeabilized with 0.5% Triton-X100 for 10 minutes at room temperature.Tissue was blocked at room temperature for 2 hours with 10% donkey serum (Jackson Laboratory, Maine), 5% BSA (Sigma-Aldrich) and MOM IgG blocking solution (Vector Laboratories, California) dissolved in 0.01% PBS-Tween20. SG sections were incubated with the following primary antibodies overnight at 4°C: rabbit anti-AQP5 (1:200, Millipore, AB3559), goat anti-SOX2 (1:200, Neuromics, GT15098), rabbit anti-Ki67 (1:200, AbCam, ab16667), rat anti-Ki67 (1:200, DAKO, M7249), rabbit CHRM3 (1:1000, Research Diagnostics, AS-3741S), rat anti-E-cadherin (1:400, Invitrogen, 13-1900). Antibodies were detected using Cy2-, Cy3-, or Cy5-conjugated Fab fragment secondary antibodies (1:300, Jackson Laboratory), and cell nuclei were stained using Hoechst33342 (1:1000, AnaSpec Inc.). EdU staining was performed using Click-iT EdU Alexa-Fluor 488 or 647 kit (Invitrogen). Slides were mounted using Fluoromount-G (SouthernBiotech) and fluorescence was analyzed using a Leica Sp5 confocal microscope. Image processing and quantification were performed using NIH ImageJ software.
[0341] statistics
[0342] Statistical tests were performed using GraphPad Prism software v8. Data are presented as mean ± SD and were subjected to two-tailed unpaired Student's t-test (for two data sets) or ordinary one-way ANOVA with Tukey's multiple comparison test (for more than two data sets). Significance was assessed using P value cutoffs as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Specific data set analyses are described in the figure legends.
Claims
1. A composition comprising a muscarinic agonist encapsulated in a hydrogel, formulated for topical intraglandular administration to the salivary glands for the treatment of xerostomia caused by damage or destruction of saliva-producing acinar cells, in, The muscarinic agonist is cevimeline, the hydrogel comprises alginate, the concentration of the alginate in the hydrogel ranges from 2 wt % to 10 wt % (weight percentage), and the alginate combined with the muscarinic agonist stimulates the proliferation of endogenous SOX2+ acinar progenitor cells and the repopulation of salivary glands and saliva-producing glandular cells.
2. The composition of claim 1, wherein the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes.
3. The composition of claim 1, wherein the alginate is ionically cross-linked.
4. The composition of claim 3, wherein the alginate is ionically cross-linked by divalent calcium ions.
5. The composition of claim 3, wherein the alginate is at least partially oxidized.
6. The composition of claim 1, wherein 2% to 10% of the alginate is oxidized.
7. The composition of claim 5, wherein 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is 5 wt%.
8. The composition of any one of claims 1 to 7, wherein the hydrogel provides sustained delivery of the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to a subject.
9. The composition according to any one of claims 1 to 7, further comprising a pharmaceutically acceptable excipient.
10. The composition according to any one of claims 1 to 7, further comprising a contrast agent.
11. Use of the composition of any one of claims 1 to 10 in the preparation of a medicament for treating xerostomia caused by damage or destruction of saliva-producing acinar cells in a subject, wherein the treatment comprises administering a therapeutically effective amount of the composition locally intragastrically to the salivary glands of the subject.
12. The use according to claim 11, wherein the composition is injected into the salivary gland.
13. The use according to claim 11, wherein the subject undergoes medical imaging or palpation to locate the salivary gland prior to injection.
14. The use according to claim 13, wherein the medical imaging comprises performing ultrasound imaging.
15. The use according to claim 11, wherein multiple therapeutically effective doses of the composition are administered to the subject.
16. The use according to claim 11, wherein the xerostomia is caused by damage to the salivary glands caused by radiation or Sjögren's syndrome.
17. The use according to claim 11, wherein the subject is a pet or livestock.
18. The use according to any one of claims 11 to 17, wherein the subject is a mammal.
19. The use according to claim 18, wherein the mammal is a dog, a cat, a horse, a cow, a goat, a sheep or a pig.
20. The use according to claim 18, wherein the mammal is a human.
21. A kit comprising the composition of any one of claims 1 to 10 and instructions for treating dry mouth.
22. The kit of claim 21, further comprising a device for delivering the composition to a subject.
23. The kit of claim 21, further comprising a first syringe comprising the composition of a muscarinic agonist encapsulated in an alginate hydrogel, a second syringe comprising a solution comprising calcium chloride, and a Luer lock, wherein the second syringe is connectable to the first syringe via the Luer lock.
24. The kit of claim 23, wherein the first syringe is in a frozen state.
25. Use of a muscarinic agonist in the preparation of a medicament for treating a subject with a low number of acinar cells or damaged acinar cells in salivary glands, wherein the muscarinic agonist is topically applied to acinar progenitor cells and acinar cells of the salivary glands to promote the proliferation of the acinar progenitor cells and acinar cells, thereby increasing saliva secretion, the muscarinic agonist is cevimeline, the muscarinic agonist is encapsulated in a hydrogel, the hydrogel comprises alginate, the concentration of the alginate in the hydrogel ranges from 2 wt% to 10 wt% (weight percentage), and the hydrogel is formulated for topical administration to the salivary glands.
26. The use according to claim 25, wherein the acinar progenitor cells are SOX2 + Acinar progenitor cells.
27. Use according to claim 25, wherein the alginate is ionically cross-linked.
28. Use according to claim 27, wherein the alginate is ionically cross-linked by divalent calcium ions.
29. The use according to claim 25, wherein the alginate is at least partially oxidized.
30. The use according to claim 29, wherein 2% to 10% of the alginate is oxidized.
31. The use according to claim 30, wherein 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is 5 wt%.
32. The use of claim 25, wherein the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes.
33. The use of any one of claims 25 to 32, wherein the hydrogel provides sustained delivery of the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to the subject.
34. The use according to any one of claims 25 to 32, wherein the acinar progenitor cells are Ki67 + or EdU + Acinar progenitor cells.
35. The use of any one of claims 25 to 32, wherein salivary flow is increased due to proliferation of the acinar cells in response to the muscarinic agonist.
36. Use according to any one of claims 25 to 32, wherein the salivary gland is a sublingual gland.
37. The use according to any one of claims 25 to 32, wherein the acinar progenitor cells are SOX2 + / AQP5 + / Ki67 + cell.
38. The use according to any one of claims 25 to 32, wherein the acinar progenitor cells are mucin (MUC) 19 - cell.
39. The use according to claim 26, wherein the SOX2 + Acinar progenitor cells are isolated from salivary glands of the subject and expanded.
40. The use according to claim 39, wherein the expanded cells are provided in an engineered tissue construct or a biocompatible matrix, and the engineered tissue construct or the biocompatible matrix can controllably release the muscarinic agonist in the expanded cells, wherein the controlled release comprises at least one of delayed release, sustained release, gradient release, time release, patterned release or spatial release.
41. The use according to claim 40, wherein the expansion cells and the muscarinic agonist are provided on and / or within a biodegradable natural polymer or macromer.
42. The use according to claim 41, wherein the biodegradable natural polymer or macromer comprises a hydrogel.
43. The use according to any one of claims 25 to 32, wherein the subject has received radiation therapy that can cause xerostomia.
